



China Pharmaceutical Guide

中国医药市场指南

15th Edition (2020)

Written by:

James J. Shen, MBA

Unrivaled China Healthcare Intelligence Since 1991

Published by WiCON International Group LLP

WiCON International Group LLC

21 Bridge Street, Metuchen, NJ 08840, USA

Tel: +1 609 903 8881 Fax: +1 801 751 5728

Internet: www.pharmachinaonline.com Email: jshen@pharmachinaonline.com

China Office

Suite 17D, Building B, Oriental Kenzo Plaza, 48 Dongzhimenwai Dajie, Dongcheng District, Beijing 100027, China

Tel: +86 10 8447 6010

Email: info@pharmachinaonline.com

Japan Office

3-10-10 Hakucho, Habikino City, Osaka Japan 583-0856

Email: info@pharmachinaonline.com

Disclaimer

While every effort has been made to ensure that information in this publication is correct, no liability can be accepted for any loss incurred in any way whatsoever by any company or individual relying on the information herein. To the best of our knowledge the information given is accurate at the date of publication.

Copyright © 2020 by WiCON International Group LLC

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means – electronic magnetic tape, mechanical, photocopying, recording or otherwise – without prior permission of the copyright owner.

ABOUT THE AUTHOR / PUBLISHER

WiCON | China Pharmaceutical Guide is authored, edited and published by James J. Shen, a veteran of the Chinese healthcare industry and market, who has dedicated his entire 32-year career to pharmaceutical businesses in China.



James Shen has rich operational and senior level management experience on China's healthcare businesses in the capacities of a senior consultant to multinational pharmaceutical companies, a manager of joint venture projects and companies, a business development executive, an entrepreneur, and most recently a publisher.

James Shen started his career in the pharmaceutical industry in 1987 when he joined Beijing Ciba-Geigy Pharmaceutical Ltd. (now Beijing Novartis) as Assistant to the General Manager. While he studied MBA in England in various periods of 1980s, he worked as an editorial consultant for Scrip/PJB Publications, IQVIA and *Financial Times* Business Information on China's healthcare news.

In 1991, he founded WiCON International Group in the USA to provide strategic consulting and competitive intelligence to international healthcare companies in order to assist and facilitate their market entry into China. He has worked with many large and mid-size international pharmaceutical companies on a diverse range of projects including entry strategy development, strategic alliances and joint ventures, marketing and distribution agreements, product registration and clinical trials, licensing and technology transfer, API sourcing, and M&A due diligence.

As an entrepreneur, James Shen co-founded *Beijing Jicai Pharmaceutical Technologies Ltd.* in 1992, one of the first private pharmaceutical research institutions in China, and took over its management in 2001. He is also a co-founder of *Nanjing Zinox Pharmaceutical Co. Ltd.*, an emerging generic pharmaceutical company in China.

James Shen was the Managing Editor of the well-known *IQVIA China Update*, a monthly newsletter covering China's pharmaceutical market co-published by IQVIA and WiCON. He authored many China healthcare business publications in English throughout 1990s, including *Marketing Pharmaceuticals in China*, *Guide to Pharmaceutical Research Institutions in China*, and *Directory of Bulk Pharmaceutical Manufacturers & Products in China*.

In early 2006, following a restructure of WiCON's businesses, James Shen founded **WiCON | Pharma China**, the highly-respected English media and business intelligence service on China's pharmaceutical industry and market which is subscribed by almost all multinational pharmaceutical companies, CROs, consulting companies and investment banking firms active in China.

James Shen was educated in China, Europe and the USA at university and postgraduate levels, and received an MBA from the University of Exeter (UK) in 1990.

He is now based in Osaka and Beijing with frequent visits to the U.S. and Europe. He continues to be active in strategic consulting with multinational pharmaceutical companies at headquarter and regional head office levels, as well as selective entrepreneurial and VC/PE investment projects in the Chinese healthcare sector.

PREFACE

Despite the enormous business opportunities and growth prospects offered by China's healthcare sector, I've witnessed and experienced countless regulatory and business environmental changes, which has frequently caused painful business difficulties, frustrations and downfalls, in my past 31 years of work in the sector as a consultant, manager and entrepreneur.

The ever-changing legal and market environments in China healthcare present the single biggest challenge to companies and executives operating in the sector. In spite of these challenges and difficulties, the Chinese pharmaceutical industry and market have achieved remarkable growth in the past two decades. The sector is generally developing towards a positive direction in the sense that it continues to grow steadily, its regulatory regime has become increasingly compatible with international standards with improving transparency, once rampant corruption is being tackled, its ongoing consolidation will eventually help establish order and stability, and the country's new healthcare reform will ultimately lead to a more stable and healthier market environment.

There are success stories from all types of players, whether they are foreign or local, large or small, newcomer or established, private or state-owned. However, to be a success story requires a thorough understanding of the sector, ability to face and tackle challenges, flexibility to deal with changes, and skills to maneuver through complex situations.

It has been my wish to put my experience and observations in the past 31 years of operating in almost every aspect of China's pharmaceutical business into a publication, which will serve as a one-stop reference to anyone seeking to enter or operate in the Chinese pharmaceutical market. As of our 2007 edition, we have been adding a rising number of commentaries and contributions from many other leading pharma industry executives and experts.

Packed with hard-to-find current data and the author's expert knowledge from years of hard-earned experience in the industry, its comprehensiveness, practicality, insight, reliable data and analysis, and up-to-date information, are the features which set this the guide apart from other publications with similar titles.

This Guide is written based on my past experience, interviews with relevant industry experts and government officials, articles from WiON|Pharma China, information obtained from or published by Chinese government agencies, information obtained from or published by independent pharmaceutical industry associations, reliable data and released exclusively to WiCON for publication from various reputable market research and consulting firms, information from other trustworthy trade journals and newspapers, related information found on the internet, and a large in-house information collection by WiCON International Group accumulated since 1991.

About WiCON | *China Pharmaceutical Guide 2020 (15th Edition)*

The WiCON | *China Pharmaceutical Guide 2020 (15th Edition)* is organized into the following four volumes:

Volume I – *Overview of the Chinese Pharmaceutical & Healthcare Sectors* (covering update of China’s business environment, history and structure of the Chinese pharmaceutical industry, Chinese health sector structure and statistics, health insurance sector structure and data, as well as disease and drug consumption patterns);

Volume II – *Chinese Pharmaceutical IP and Regulatory Guide* (covering the Chinese drug regulatory system overview, summaries of major healthcare/pharmaceutical related laws and regulations, government agencies and industry associations and pharma IP strategies & legal issues);

Volume III – *Annual Review, Trends, Opportunities and Strategic Considerations* (including a complete review of latest data, business trends, regulatory & IP/legal developments and healthcare reform progress of the Chinese pharmaceutical industry and market in 2019/1H2020, and a large collection of feature articles from industry experts relating to competemporary trends, issues and strategic considerations as well as promising opportunities of the present and future); and

Volume IV – *Sales & Marketing, Entry Strategies and Case Studies* (covering orientation, models and strategies of pharmaceutical sales, marketing and distribution in China, marketing entry strategies and execution, case studies featuring success stories of MNCs and domestic players, R&D and outsourcing, human resource management and legal/IP issues), as well as appendices with full texts of important healthcare/pharma related policies, laws and regulations.

It is thoroughly updated with ample latest data from many reputable sources, abundant analysis by leading industry experts, new regulations and more case studies. Its coverage was renewed and expanded significantly in the following areas:

- ☞ Hundreds of pages of new data, information, analysis and case studies.
- ☞ Thorough summaries and analysis of the latest healthcare reform, drug pricing & reimbursement and hospital tender purchase policies, as well as coverage of the most recent government reorganization relating to healthcare and drug regulation.
- ☞ Comprehensive industry, market and international trade data as well as health statistics are updated with the 2019 (full year) and available data for H1/2020.
- ☞ Expanded coverage on IP, patent and anti-monopoly-related laws and regulations, e-commerce and digital marketing opportunities, the primary healthcare sector, the OTC and consumer healthcare sector, high-growth market segments, key regional hospital markets, and the pharmaceutical distribution sector,

- ☞ Updated coverage of the Chinese biosimilars/biologics market prospects and regulatory outlook.
- ☞ Updated coverage of emerging legal issues (including FCPA/compliance and liability issues) and drug-related IP and trademark concerns.
- ☞ Comprehensive top line data, research findings and observations from our collaborative partners such as IQVIA, Kantar Health, Nicholas Hall, ZS Associates and RDPAC, as well as other reputable sources including the Chinese Pharmaceutical Association, SMEI, PHIIC and Sinohealth.
- ☞ All regulatory changes in 2019/1H2020 are updated to present a clear and most up-to-date picture of the Chinese drug regulatory framework with summaries and analysis of all pharmaceutical related regulations in effect by mid-2020.
- ☞ Focused coverage of China's ongoing efforts to revamp its drug regulatory regime through amendments of the *Drug Administration Law*, the proposed *Vaccine Management Law*, the transformation of drug pricing mechanism, deepening reform of the drug registration and evaluation regime, new policies to support drug innovation, biosimilars and high clinical value generics, and the initiative to re-evaluate all generic drugs with bioequivalence studies.
- ☞ Extensive review and analysis of China's drug registration applications and approvals as well as Chinese drug innovation trends in recent years.
- ☞ Comprehensive review of Sino-foreign M&A, joint venture, strategic alliance, licensing, research partnerships and new drug R&D events in 2019 and H12020.
- ☞ Expanded coverage on MNC performance and strategic considerations in China with healthcare reform in the backdrop, intellectual property/patent law amendments, data exclusivity, patent litigation, drug regulations, pharma marketing and distribution strategies, drug consumption patterns, the Chinese R&D and outsourcing sector, clinical studies/practices, healthcare reform, community healthcare sector, essential drug policy, regional drug consumption patterns, and the vaccine and API sectors.
- ☞ In addition to the existing five key case study areas, two more areas on pharma's alliance with health insurance companies and with e-commerce/digital health providers are added. Numerous new case studies are added, as existing cases are updated and filtered.

I would like to take the opportunity to thank all those organizations and individuals who contributed to this publication and their continued cooperation is greatly appreciated.

James J. Shen

July 30, 2020

TABLE OF CONTENTS

VOLUME 1 OVERVIEW OF THE CHINESE PHARMACEUTICAL & HEALTHCARE SECTORS.....	1
ABOUT THE AUTHOR / PUBLISHER	3
PREFACE	5
TABLE OF CONTENTS.....	9
LIST OF TABLES.....	17
LIST OF CHARTS.....	37
TABLE OF ABBREVIATIONS.....	39
EXECUTIVE SUMMARY.....	41
PART I OVERVIEW OF THE CHINESE PHARMACEUTICAL SECTOR.....	53
Chapter I-1 China’s Broad Business Environment.....	55
1.1 Fast Economic Growth and Change.....	55
1.2 Integration into the World Economy	56
1.3 Economic Reform	57
1.4 WTO Entry Brought Further Reform and Regulatory Changes, Despite Problems and Issues	60
1.5 Demographic Trends and Challenges.....	65
1.6 Rising R&D Investments and Patent Applications	73
1.7 Foreign Investment: Structure, Trends & Outlook.....	76
1.8 How to Use China’s 2019 Negative Lists	84
1.9 Slowing Chinese Economy Search for A Bottom with Phase 1 U.S.-China Trade Deal.....	88
1.10 Looking Back on 2019 and What Can We Expect in China in 2020?.....	92
1.11 What is the True Size and Growth of Chinese Economy?	97
1.12 Revisiting the Basis of Your China Strategy in the Post-Covid New Normal.....	99
1.13 China’s Economic Rebound in 2020 Slower Than Expected.....	100
1.14 Business Climate and Outlook – Surveys of Foreign Companies in China	103
1.15 AmCham Survey: Supply Chain Challenges for US Companies in China	108
1.16 Dealing with the Chinese Economy After COVID-19.....	109
1.17 Foreign Firms Brace for Turmoil in China.....	112
1.18 Multinationals to Shift Supply Chains out of China in 2020 – MUFG.....	113
1.19 Key Findings of the U.S.-China Economic and Security Review Commission Report – Cascading Economic Impacts of the COVID-19 Outbreak in China	114
Chapter I-2 Background: The Chinese Pharmaceutical Sector.....	115
2.1 Introduction.....	115
2.2 Government Guidelines for Pharmaceutical Industry Development.....	122
2.3 Pharmaceutical Sector Reform As A Part of Healthcare Reform	132

Chapter I-3 Overview: The Chinese Pharmaceutical Industry	141
3.1 Overview	141
3.2 The Pharmaceutical Formulation Sector	144
3.3 The Bulk Drug/Active Pharmaceutical Ingredient and Excipient Sector	148
3.4 The Biopharmaceutical Sector	164
3.5 The Human Vaccine Sector	175
3.6 The Pharmaceutical Distribution Sector	185
3.7 Pharmaceutical R&D in China – Domestic Chinese Companies	194
3.8 Pharmaceutical R&D in China – Foreign Companies	201
3.9 Pharmaceutical Outsourcing Sector (CRO and CDMO)	210
3.10 China's Innovative Turn and the Changing Pharmaceutical Landscape	216
3.11 M&A and Venture Capital Investment in the Pharmaceutical Industry	224
3.12 Leading Pharmaceutical Companies in China	228
3.13 Leading Pharmaceutical Distributors	238
3.14 Leading Retail Pharmacy Chains in China	239
3.15 Leading Chinese CRO and CDMO/CMO Companies	239
3.16 China Prepares for Big Pharma	241
Chapter I-4 Foreign Investment in The Pharma Industry	243
4.1 China's Foreign Investment Regulatory Framework	243
4.2 Major Tax Categories for FIEs and Foreigners	257
4.3 Forms of Foreign Investment in the Pharma Sector	260
4.4 Encouraged, Restricted and Banned Areas for Foreign Investment in the Pharmaceutical Industry	260
4.5 Growth of Foreign Investment in the Pharma Sector	265
4.6 Contemporary Trends, Issues and Strategic Considerations for Foreign Investment in the Pharmaceutical Industry	272
4.7 Three Holistic Advices to Pharma MNCs in China	283
4.8 After Giant Pharma Push, China Keeps Indian Drug Makers Waiting	285
4.9 China Accelerated Approvals of New Drugs from Foreign Countries	287
Chapter I-5 The Ethical Pharmaceutical Market	289
5.1 Market Size	289
5.2 Market Prospects and Future Outlook	292
5.3 Special Characteristics of the Chinese Ethical Pharmaceutical Market	294
5.4 The Hospital Drug Market	295
5.5 The Rise of Retail Pharmacy Sector	299
5.6 Rural Chinese Market for Ethical Drugs	308
5.7 Rising Importance of the Primary Healthcare Drug Market	311
5.8 Chinese Biologic Market Growth Expected to Accelerate	312
Chapter I-6 The Chinese Vaccine Market	320
6.1 Chinese Vaccine Market Landscape	320

6.2	Vaccine Consumption by Major Urban Chinese Hospitals	324
6.3	Market Outlook of the Chinese Human Vaccine Market	324
6.4	Chinese Human Vaccine Market Driven by HBV, Meningococcal, HAV, Influenza, Hib, Rabies and Varicella Vaccines	329
6.5	Asia-Pacific Influenza Vaccines Market to Surpass \$1.7B by 2022	330
Chapter I-7 The OTC Pharmaceutical Market		332
7.1	Overview of the Chinese OTC Market	332
7.2	Regulatory Progress on OTC Drugs	334
7.3	Chinese OTC Drug Market under Rapid Transformation	336
7.4	Enthusiastic Pharmaceutical Industry Seeks to Expand OTC Drug Sales	337
7.5	Drug Companies Foray into Consumer Healthcare to Counter Pharma Pitfalls	339
7.6	Healthcare Reform Casts Shadow on Future of the Retail Pharmacy Sector	341
7.7	CFDA Considers Ban of OTC Drug Ads on Mass Media	341
7.8	Chinese Study Finds No Prescription Necessary in Many Pharmacies	343
Chapter I-8 Pharmaceutical Import and Export		346
8.1	Background	346
8.2	Present State of China's International Trade of Medicines and Health Products	347
8.3	Custom Duties on Drug Import	349
8.4	ANDA Approvals Boost Chinese Pharma's Global Ambitions	351
8.5	Trends and Outlook	353
PART II HEALTHCARE PROVISION AND FINANCING		355
Chapter II-1 Overview		357
1.1	Improving Healthcare Provision	357
1.2	Rising Lifespan and Health Literacy of the Chinese Population	360
1.3	Composition of the Chinese Population	362
1.4	Ageing in China: The Implications for Healthcare	365
1.5	Economic Burden from Chronic Diseases May Slowdown China's Growth	367
1.6	2019 Annual Health Sector Development Report	368
1.7	Health China 2020 Strategic Research Report	381
1.8	The National Planning Guideline for Healthcare Service System (2015–2020)	383
1.9	Healthy China 2030 Plan	386
1.10	State Council Issues the Action Plan for Healthy China Initiative	388
1.11	China's Health Protection Gap Largest in Asia	389
1.12	Chinese Health Expenditure Projected to Reach 9.1% of GDP by 2035	390
1.13	China's Healthcare Crisis: Both Rich and Poor Travel Abroad	391
1.14	Central Government Issues New Policy for Healthcare Sector Development by 2022	392
1.15	Chinese Health Authorities Pledge to Prioritize Rural Development	394
Chapter II-2 Structure and Composition of Medical Provision		395
2.1	Composition of the Chinese Medical Sector	395

2.2	Grade Structure of Chinese Medical Institutions	398
2.3	Regional Distribution of Healthcare Resources	400
2.4	Distribution of Healthcare Resources by Medical Specialty	404
2.5	Human Resources in China’s Healthcare Industry.....	405
2.6	Growing Sector of Private Healthcare Providers in China	407
2.7	China Seeks to Establish a General Practitioner System by 2020	408
2.8	Government Encourages the Formation of Medical Service Consortiums	410
2.9	Telemedicine Industry To Take Off on Policy for Internet + Healthcare Development.....	413
2.10	Internet Economy to Save China CNY 610B Healthcare Expenditures Annually by 2025 ..	415
Chapter II-3 Healthcare Reform		418
3.1	A Review of China’s Healthcare System Reform in the Past Three Decades	418
3.2	Chinese Leadership Mapped A New Blueprint of Healthcare Reform	426
3.3	The Healthcare Reform Plan in the 13th FYP (2016-2020).....	428
3.4	Major Healthcare Reform Achievements in 2019 and Direction for 2020	434
Chapter II-4 Healthcare Financing and Insurance Programs		438
4.1	BMI Enrollment and Healthcare Financing in China.....	438
4.2	2019 National Basic Medical Insurance Sector Development Report	445
4.3	Urban Employee Basic Medical Insurance (UEBMI) and Maternity Insurance.....	447
4.4	Urban Resident BMI Program and New Rural Cooperative Medical Scheme	450
4.5	Critical Illness Insurance Coverage for Urban and Rural Residents	454
4.6	Work-related Injury Insurance Program.....	455
4.7	Medical Assistance Program for Civil Servants.....	456
4.8	Medical Assistance Program for the Poor.....	457
4.9	NHSA’s Annual Healthcare Security and BMI Sector Development Reports in 2019	459
4.10	Commercial Health Insurance.....	465
4.11	China’s Health Insurance Dilemma	471
4.12	Controversial Answer to China’s Health Insurance Needs	474
4.13	Chengdu: The First Steps Towards Mutual Insurance in China.....	475
4.14	MOHRSS Issues Internet+ Action Plan, Citing BMI Settlement by Social Security Card via Payment Services	477
4.15	Notice to Divide Fiscal Responsibilities of Central and Local Governments for Healthcare	477
4.16	Provisions for Health Insurance Administration	478
4.17	Opinions on Deepening Medical Insurance System Reform	480
Chapter II-5 Drug Reimbursement.....		484
5.1	Drug Reimbursement under BMI, WRI and MI Programs	484
5.2	NHSA and MOHRSS Issue 2019 NRDL under the BMI, WRI and Maternity Insurance	484
5.3	NHSA Sets Timeline for Phasing Out Provincial Level Additions of NRDL	486
5.4	NHSA and MOHRSS Conclude Negotiations for the NRDL Category B Listing.....	486
5.5	The 2020 NRDL Revision Work Plan and Application Guidelines	488
5.6	Rationalized Medicine Drug List of the Chinese Military (RMDL).....	491

Chapter II-6 Measures of Healthcare Cost-containment	492
6.1 Price Control.....	493
6.2 Centralized Hospital Drug Purchase Tenders.....	498
6.3 The National Essential Drug System	521
6.4 National Formulary and Clinical Guidelines	532
6.5 Clinical Pathway/DRGs	534
6.6 Drug Prescription Review Guidelines of Medical Institutions.....	541
6.7 National Drug Price Negotiation.....	542
6.8 National Adjuvant Drug List.....	545
6.9 Drug Consumption Surveillance and Overall Clinical Appraisal of Drug Products	547
6.10 Health Technology Assessment (HTA) for BMI Reimbursement Listing.....	548
6.11 Pharmacy Affairs Management of Medical Institutions.....	549
6.12 Plan for Generic Drug Supply Security and Use Policies	552
6.13 Tiered Medical Service System.....	554
6.14 The “Two Invoice System” in Public Hospital Drug Procurement.....	555
6.15 Other Cost-containment Measures.....	557
6.16 NHTA to Step Up Fraud Crackdown with New Document on BMI Fund Regulation	559
6.17 China's Medical Inflation Rate Is the Third-Lowest in Asia	560
PART III DISEASE AND DRUG CONSUMPTION PATTERNS.....	563
Chapter III-1 Growth of Drug Consumption and Demand	565
1.1 Sharp Growth in Drug Consumption and Healthcare Expenditures	565
1.2 The State of Health of the Chinese Population	569
1.3 Health Awareness and Literacy	570
1.4 China’s Struggle With Demographic Change	570
1.5 Medical and Public Health Services	572
Chapter III-2 Popular Diseases and Morbidity	574
2.1 Leading Diseases	574
2.2 Leading Causes of Death	580
2.3 An Extensive Overview of Chronic and Epidemic Diseases in China.....	583
2.4 Recent Trends with Cancer Challenges in China.....	608
2.5 Finally, China Comes to Grips with Its Cancer Epidemic.....	618
2.6 Prevalent Health Problems of Senior Citizens in China.....	620
2.7 Medium and Long Term Plan for Prevention and Treatment of Chronic Diseases	621
2.8 China Sets Up National Framework for Prevention and Treatment of Rare Diseases	622
Chapter III-3 Medical Institution Attendance and Expenses.....	624
3.1 Composition of Medical Care System in China.....	624
3.2 Hospital Attendance	625
3.3 Healthcare Expenditures and Medical Expenses	631

Chapter III-4 Drug Consumption Patterns in Medical Institutions.....	634
4.1 Patterns of the Chinese Hospital Drug Market	634
4.2 Drug Consumption in Chinese County Level Hospitals	650
4.3 Drug Consumption of Public Primary Healthcare Facilities.....	655
4.4 Drug Consumption of Urban Community Healthcare Centers	656
4.5 Drug Consumption in Rural Township Health Centers.....	662
4.6 Fastest Growing Products in the Top 200 Drugs by Sales Value in Rep Hospitals	664
4.7 Chemical Drug Consumption of Chinese Public Medical Institutions	666
4.8 Vaccine Consumption of Major Urban Chinese Hospitals.....	673
4.9 Hospital Sales of 25 Drug Products under 4+7 Trial	676
Chapter III-5 Retail Drug Consumption Patterns.....	677
5.1 Overview of the Chinese Pharmaceutical Retail Sales	677
5.2 Consumption Patterns of Retail Pharmacy Sales of Medicine and Health Products	685
5.3 Structure of Chinese B2C Online Pharmacy Market	699
Chapter III-6 Consumption Patterns of OTC Drugs.....	702
6.1 Structure of Chinese OTC Drug Market	702
6.2 Leading Chinese OTC Companies and Brands.....	713
6.3 China OTC Market Has Growth Potential Despite Regulatory Uncertainty	715
Chapter III-7 Regional Drug Consumption Patterns	719
7.1 Gap Between Cities and Rural Areas	719
7.2 Regional Hospital Markets for Drug Products.....	720
7.3 Hospital Drug Sales Champions in 22 Chinese Cities/Regions	729
7.4 Regional Markets by Pharmaceutical Distributor Sales.....	730
7.5 Regional Retail Pharmacy Markets for Drug Products.....	734
7.6 Regional Primary Healthcare Drug Markets.....	739
7.7 Regional Spending of the Chinese Basic Medical Insurance System	739
Chapter III-8 Market Shares of Local, JV and Imported Drugs	742
8.1 Hospital Market – Domestic vs. MNC Drugs.....	742
8.2 Retail Pharmacy Market – Domestic Companies vs. JV/Foreign Players	753
8.3 Future Trends and Outlook	754
Chapter III-9 High Growth Market Segments.....	756
9.1 Overview of Chinese Oncology Drug Market	757
9.2 The Chinese Diabetes Drug Market.....	774
9.3 The Chinese Cardiovascular Drug Market.....	784
9.4 The Chinese Hepatitis Drug Market	787
9.5 Chinese Asthma and COPD Drugs Markets Poised for Steady Growth	789
9.6 The Chinese Drug Market for Mental Disorders Has Huge Potential	792
9.7 Prospects of Chinese Pediatric Drug Market	793

9.8	Emerging Orphan Drug Market Is Hope for Millions of Chinese with Rare Diseases	794
9.9	Chinese Geriatric Drug Market Offers Great Potential	799
9.10	Alzheimer's Is China's Biggest Future Health Problem and Healthcare Opportunity	800
9.11	Chinese Hospital Drug Market for Parkinson's Disease Growing at Double Digit Rates.....	805
9.12	Bispecific Antibodies in China	805
9.13	Targeting the Affluent: Differential Access to Targeted Therapies in China	808
9.14	The TKI Lung Cancer Market in China	812
9.15	Fierce Competition in China's Nascent Immuno-Therapy Cancer Drugs Market Could Compromise Safety	816
9.16	China Prostate Cancer Market Analysis and Forecast 2019 to 2025	818
9.17	Chinese Transmucosal Delivery Drug Market to More Than Double by 2027	818
9.18	IQVIA: Review and Outlook of Chinese Drug Market for NCDs	819
9.19	The Chinese Drug Market for Three Key Chronic Diseases (Anti-hypertensives, Oral Hypoglycemics and Lipid-reduction Drugs)	822
9.20	Chinese Transmucosal Drug Delivery Systems Market to Rise 11% CAGR Before 2027 ...	834
9.21	Asia Pacific and Chinese CRO Market Value Projected to Expand By 2025	835
9.22	China, The World's Second Largest Clinical Nutrition Market	836
9.23	Chinese Precision Medicine Market Set to Witness a Robust CAGR of 12.82%	836
9.24	Chinese Innovative Drug Sales 2013-2019E	837
9.25	Chinese Human Vaccine Market Prospects Rosy	838
Chapter III-10 Snapshot of Generic Chemical Drug Consumption		840
10.1	Overview of the Chinese Generic Drug Market.....	840
10.2	IQVIA/McKinsey: Generics Continue to Dominate Chinese Pharma Market.....	842
10.3	SMEI: Chinese Hospital Chemical Drug Sales Up 4.14% in 2019	843
10.4	Top Chemical Drug Products in Urban Chinese Retail Pharmacies 2018	847
VOLUME 2 CHINESE PHARMACEUTICAL IP AND REGULATORY GUIDE		851
TABLE OF CONTENTS.....		853
LIST OF TABLES.....		857
LIST OF CHARTS.....		860
TABLE OF ABBREVIATIONS.....		861
PART IV CHINESE PHARMACEUTICAL REGULATORY AND IP GUIDE .		863
Chapter IV-1 Overview.....		865
1.1	Drug Regulatory Statistics	865
1.2	Overview of Drug Evaluation and Registration in Recent Years	867
1.3	Review of Drug Applications under Special Approval, National S&T Major Project and Priority Review Paths with CDE 2004-2019	881
1.4	Adverse Drug Reaction Reporting	884

1.5	National Drug Abuse Monitoring Annual Report	885
1.6	NIFDC Issues the 2019 National Drug Sample Inspection Annual Report	886
1.7	Review of New Chinese Pharmaceutical/Healthcare Regulations in 2019 and H1/2020	887
1.8	Major Drug-related Policies, Regulations and Laws under Drafting Process	891
1.9	NMPA to Complete Legal Framework for Food and Drug Regulation by 2020.....	893
1.10	Drug Regulatory Reform Direction in 2020	894
1.11	Reform of China’s Drug Evaluation and Approval System	896
1.12	Chinese Generic Drug Applications Rebound in 2018 After Two-Year Decline	910
1.13	China Joins ICH in Pursuit of Global Harmonization of Drug Development Standards	911
1.14	NMPA Issues Action Plan for Accelerated Advancement of Intelligent Drug Regulation....	912
1.15	Highlights of the 2020 Amendments of the Provisions for Registration of Drug Products and the Provisions for Control of Drug Manufacture on MNC Pharma	913
1.16	Hainan Medical Tourism Zone: New Pilot Policies Rolled Out	915
Chapter IV-2 Important Laws and Regulations		918
2.1	The Drug Administration Law of the People's Republic of China.....	918
2.2	Regulations for Implementation of the Drug Administration Law of the PRC.....	921
2.3	The Vaccine Management Law of PRC	927
2.4	Major Regulations under the Drug Administration Law of PRC.....	928
2.5	Other Drug Related Laws and Regulations.....	931
Chapter IV-3 Major Government Agencies and Industry Associations in The Pharma Field		935
3.1	State Administration of Market Regulation (SAMR)	936
3.2	The National Medical Products Administration (NMPA) under the SAMR.....	938
3.3	The Center for Drug Evaluation under the NMPA	944
3.4	The National Health Commission (NHC).....	946
3.5	National Healthcare Security Administration (NHSA).....	951
3.6	Ministry of Human Resources and Social Security (MOHRSS)	954
3.7	Ministry of Industry and Information Technology (MIIT)	955
3.8	Ministry of Commerce (MOFCOM or MOC)	955
3.9	National Development and Reform Commission (NDRC).....	956
3.10	Inter-ministerial Conference for Vaccine Regulation.....	959
3.11	State-owned Assets Supervision and Administration Commission of the State Council (SASAC)	959
3.12	State Administration of Traditional Chinese Medicine (SATCM)	960
3.13	China National Intellectual Property Administration (CNIPA).....	961
3.14	Pharmaceutical Industry Associations in China	963
Chapter IV-4 Drug Regulatory Framework in China (1) - Drug Registration Regime		968
4.1	Overview of Drug Registration Reform.....	968
4.2	Overview of the Provisions for Registration of Drug Products (2020).....	974

4.3	Clinical Research for Drug Registration	980
4.4	Rules, Standards & Technical Guidelines / Drug Evaluation Management	987
4.5	Special Approval / Priority Review of Drug Registration	994
4.6	Registration of Copy/Generic Drugs and Generic Quality and Clinical Equivalence (GQCE) Evaluation.....	1000
4.7	Registration of Import Drugs	1014
4.8	Re-Registration of Imported Drugs.....	1018
4.9	Registration of Biosimilars	1019
4.10	Registration of OTC Drugs	1020
4.11	Registration of Certain Drug Related Products, Foods for Medical Purpose and Health Foods	1020
4.12	Application and Approval of Supplemental Registrations	1024
4.13	Drug Registration Reconsideration	1025
4.14	Post Approval Changes to Pharmaceuticals	1027
4.15	Onsite Verification for Drug Registration	1027
4.16	Linked Review and Approval of APIs, Pharma Excipients and Packaging Materials	1028
4.17	Chinese Pharmacopoeia (ChP) and Drug Standards	1032
4.18	GLP for Preclinical Research and GCP for Clinical Research	1034
4.19	China Launches Drug Marketing Authorization Holder (MAH) System.....	1040
4.20	Conditional Approvals For New Drugs, Compassionate Use Of Investigational Drugs and Use of Real-World Data to Support Drug R&D and Evaluation	1047
4.21	Nature Determination of Drug and Device Combination Products.....	1051
4.22	Rare Diseases and Orphan Drugs.....	1052
4.23	Interpretations for Application of Criminal Laws for Faking Drug and Medical Device Registration Data.....	1052
Chapter IV-5 Drug Regulatory Framework in China (2) – Others		1054
5.1	Pharmaceutical Manufacturer Licensing, Manufacturing and GMP.....	1054
5.2	Regulation of Pharmaceutical Excipients	1059
5.3	Drug Labeling and Packaging.....	1061
5.4	Pharmaceutical Distribution and Distributor Licensing.....	1065
5.5	Vaccine Distribution.....	1076
5.6	Drug and Excipient Import Process	1081
5.7	Pharmaceutical Regulatory Inspections and Enforcements	1086
5.8	Classified Control of Prescription and Non-prescription Drug Products	1090
5.9	Drug Advertising.....	1093
5.10	Drug Pricing and Price Control.....	1100
5.11	Post-marketing Surveillance/ADR Reporting/Tracing.....	1108
5.12	Counterfeit, Fake and Sub-standard Drugs	1117
5.13	Control of Narcotic, Psychotropic and Radioactive Drugs	1120
5.14	Internet Information Service and Online Sales of Drug Products	1125
5.15	Drug Prescription/Rational Drug Use/Clinical Practices/Chinese Orange Book	1129

5.16	Pharmaceutical Technology Transfer / Administrative Protection / IP	1141
5.17	Anti-corruption/Compliance/Black Listing/Confidentiality	1150
5.18	Drug Donations.....	1167
5.19	International Regulatory Cooperation.....	1176
5.20	Drug Import & Export Control and Certifications	1186
5.21	Medical Representative Registration	1188
5.22	Others.....	1190
Chapter IV-6 Intellectual Property Rights and Legal Issues		1194
6.1	Pharmaceutical Patent Protection	1212
6.2	Compulsory Licensing.....	1252
6.3	Data Exclusivity and Trade Secret Protection.....	1257
6.4	Patent and Trademark Registration.....	1265
6.5	Patent and IP Strategies for China	1274
6.6	Enforcing Patents – China's Bad Faith Entities List	1276
6.7	Protecting and Policing IPRs in China.....	1278
6.8	Patent Invalidation Strategies in China.....	1283
6.9	Pharmaceutical Patent Litigation in China.....	1288
6.10	Importance of Patents in Chinese Pharmaceutical Tendering	1292
6.11	Counterfeit Drugs.....	1295
6.12	Judicial Interpretations of Law Applications over Drug Safety	1297
6.13	The Tort Liability Law: Impacts on Pharma	1303
6.14	Considerations for Compliance and Corruption Risks.....	1308
6.15	Antitrust/Antimonopoly.....	1325
6.16	A Comprehensive Overview of Pharmaceutical Antitrust in China.....	1340
6.17	Big Data Policy and Legal Issues in the Healthcare Industry	1362
6.18	New Challenges Ahead: How to Comply with Cross-Border Data Transfer Regulation in China	1369
6.19	Health Care Data Compliance in China: FAQ	1373
6.20	The Impact of Scientific Data Administrative Measures on Foreign Companies in China.	1376
6.21	How Data Protection Matters for Pharmaceutical Companies in Mainland China? – Ensuring Compliance and Mitigating Risk.....	1381
6.22	Regulation on the Management of Human Genetic Resources.....	1387
6.23	Intellectual Property Theft	1387
6.24	A Guide to the Two Invoices System in Chinese Pharmaceuticals Distribution	1391
6.25	In Depth: Decoding China's First Civil Code	1393
6.26	Punitive Damages in China's New Civil Code.....	1396
VOLUME 3 ANNUAL REVIEW, TRENDS, OPPORTUNITIES & STRATEGIC CONSIDERATIONS.....		1401
TABLE OF CONTENTS		1403
LIST OF TABLES		1408

TABLE OF ABBREVIATIONS.....	1413
PART V ANNUAL REVIEW AND OUTLOOK OF THE CHINESE PHARMACEUTICAL INDUSTRY AND MARKET.....	1415
Chapter V-1 The Broad Chinese Economy: Review and Outlook.....	1417
Chapter V-2 Annual Review of the Chinese Pharmaceutical Industry and Market..	1420
2.1 Data Overview: Chinese Pharmaceutical Market Landscape	1420
2.2 Data Overview: Pharmaceutical Industry Performance	1435
2.3 China Performance of Foreign Pharma Companies in 2019 and H1/2020	1441
2.4 Performance of Domestic Pharmaceutical Companies in 2019 and H1/2020.....	1455
2.5 Paradigm Begins to Shift for Chinese Pharma as MNCs Struggle to Fit in with the New Normal	1461
2.6 Review of Regulatory Developments in 2019 and H1/2020.....	1470
2.7 Healthcare Reform Remains in Deep Water and Preoccupied with Cost Containment Growing Shortages	1476
2.8 China Sends Conflicting Signals in the Field of Pharma IP but the U.S.-China Phase 1 Trade Deal May Be A Game Changer.....	1487
2.9 China Pushes New Generic Drug Policy to Undermine MNCs amid Threat of Trade War ..	1497
2.10 NMPA/Yaozh Publish Analytical Report on Approved GQCE Reference Drugs	1499
2.11 How Did Drugmakers Brace for China's Biggest-Ever Rounds of Price Cuts in Early 2020?	1499
2.12 China's Blueprint for Its Pharmaceutical Sector	1502
2.13 Be Ready for the Dire Aftermath of the Post-Pandemic China Market	1508
2.14 Despite the Storms Ahead, Pockets of Hope and Opportunity Remain	1510
Chapter V-3 Review of Chinese Pharma M&A, Licensing and Collaborative R&D Deals / IPO events	1515
3.1 M&A, Licensing and Collaborative R&D Deals in 2019 and 1H/2020.....	1515
3.2 Chinese Biopharma Startups Raised \$1,645M and Launched Seven IPOs in H1/2019.....	1541
3.3 HK and Shanghai Star Listings to Boost Expansion of Chinese Biotechs	1542
Chapter V-4 What Does the Future Hold for China's Healthcare Economy?	1544
4.1 Chinese Pharma Remain Trapped in Clouds as Industry Recalibrates.....	1544
4.2 Despite Challenges and Mixed Outlook, Long-Term Prospects and Opportunities Remain	1548
4.3 The Godsend Window of Opportunity for MNCs To Recalibrate China Strategy and Reallocate Resources	1556
4.4 13th FYP Paints a Gloomy Picture for Healthcare MNCs	1558
4.5 Harvard Researchers Recommend New System to Improve China Healthcare.....	1561
4.6 China Still Needs MNC Pharma Companies More Than The Other Way Round.....	1562
4.7 What Is The 2018 Reorganization of China's Healthcare Agencies Really About?	1565
4.8 China Pushes Generics over Brands with Another Round of New Pharma Policies.....	1567
4.9 China Boosts Support of Anticancer and Orphan Drugs thru Tax and Price Cuts	1569

4.10 U.S.-China Trade Deal Shows Potential for Improved U.S. Intellectual Property Rights in China	1573
4.11 Pharma and MedTech Outlook Clouded by Coronavirus Outbreak	1576
PART VI CONTEMPORARY TRENDS, OPPORTUNITIES AND STRATEGIC CONSIDERATIONS.....	1579
Chapter VI-1 Introduction	1581
Chapter VI-2 Market Dynamics and Strategic Considerations.....	1583
2.1 What Should We Know about the Merger of China’s Urban and Rural Resident Basic Medical Insurance Schemes?	1583
2.2 China: A Change in Attitude	1585
2.3 Finally, China Comes to Grips with Its Cancer Epidemic	1589
2.4 Cross-Sector Collaboration to Enhance Market Access for Pharmaceutical Companies in Asia: Six Steps to Make It Work.....	1590
2.5 The View of China from Headquarters	1594
2.6 Are You Ready for the Lower Tier Market?	1596
2.7 Why Chinese Drugmakers Are Looking Overseas	1597
2.8 Review of Off-label Drug Usage in Chinese Hospitals	1599
2.9 China Healthcare Advertising: Failure to Learn	1600
2.10 China's Life Science Innovative Development Policies.....	1601
2.11 Strategic Domains in the U.S.-China Life Science Sector	1603
2.12 Can Technology Really Solve China's Healthcare Crisis?.....	1604
2.13 Pharma MNCs are on the Defensive. Are They Thinking Clearly?	1606
2.14 Generic Consistency Evaluation in China: The Coming Paradigm Shift in Drug Pricing and Patent Cliff	1608
2.15 Reimagining the Pharmaceutical Sales Rep Model in Asia	1611
2.16 Issues in Chinese Foreign Direct Investment in U.S. Early Stage Biotechnology Cos.....	1613
2.17 Trick or Treat? China Announces New Initiatives to Level the Playing Field for Innovative and Generic Drugs	1615
2.18 Can China’s R&D Sector Shake Its Reputational Issues?.....	1617
2.19 Chinese Pharma and Biotech Companies Tap U.S. Talent.....	1619
2.20 Production of Trustworthy Real World Data and Evidence in China.....	1620
2.21 China’s Crackdown On Genetics Breaches Could Deter Data Sharing	1622
2.22 How China’s Protectionist Vaccine Policy Has Backfired on Beijing	1624
2.23 Trade Bodies Warns API Supply Chain Disruptions from Chinese Plant Closures	1627
2.24 Kangmei’s \$4bn Accounting Error Highlights China Risk.....	1628
2.25 China: Survival of the Fittest or Cheapest?	1630
2.26 Celebrity Doctor Pay Exposes China’s Healthcare Gap	1634
2.27 Impact of the China-U.S. Trade Deal on IP Protection Related Professionals.....	1636
2.28 Next Up In China Trade War: Biotech Purge?	1639
2.29 Drugmakers Braced for Coronavirus Disruption to China Supplies.....	1641
2.30 U.S. Senior Official Urges to Reduce Dependence on Chinese Drug Supplies	1643

2.31	Coronavirus A Growing Threat to Global Supply Chains – Pharma Hit First	1645
2.32	International Generic Drugmakers Have A China Dependency Problem	1645
2.33	China's Biopharma Strategy: Challenge or Complement to U.S. Competitiveness?	1648
2.34	U.S. Is Investing Millions to Bring Drug Making Back from China and India	1649
2.35	Crowdfunding Can't Cure China's Health Care.....	1651
2.36	Challenges Posed to Chinese Biotechs in Post-Pandemic Era	1653
Chapter VI-3 Promising Opportunities of the Present and Future		1656
3.1	China's Biopharma Rise: Opportunities and Threats	1656
3.2	Trade Tensions Undermines Flow of Chinese VC to US Biotechs	1658
3.3	MNCs Boost Drug Research and Clinical Trials for Diseases Prevalent in China and Other Asian Markets.....	1659
3.4	Why Big Pharma Is Targeting China's Deadliest Diseases	1661
3.5	Pharma Companies May Benefit from Proposed Patent Law Changes in China.....	1663
3.6	Review of Class 1 New Drug Applications and Approvals 2003-2019	1664
3.7	Review of New Drugs Under Development in China in 2019 and H1/2020	1670
3.8	NMPA Designated Foreign New Drugs in Urgent Clinical Need – How Things Stand?.....	1676
3.9	Why Chinese Biotech Inventions Have Yet To Make An Impact Globally, Despite Patenting Surge.....	1678
3.10	Can A Cancer Drug Originated in China Be A Success in the U.S.?	1680
3.11	Understanding China's Marketing Authorization Holder Pilot Plan in Selected Regions...	1681
3.12	China Embraces Precision Medicine on a Massive Scale	1682
3.13	Building a Translational Medicine Powerhouse in China	1684
3.14	China Biotech Promise Struggles to Keep Foreign Innovators.....	1689
3.15	McKinsey: Running on the China Bridge to Innovation.....	1691
3.16	Local Partnerships Key to Pharma's Success in China	1693
3.17	The Biosimilar Race in China.....	1695
3.18	Biosimilars and Healthcare Policy: What China Can Learn from EU and US	1699
3.19	Who Will Win the PD-1 War in China?	1699
3.20	Branded Generics in the Emerging Markets	1703
3.21	New Opportunities in Emerging Markets	1704
3.22	Fear of Substandard Medicines Led to Opportunities for US Pharma in China	1708
3.23	Biopharma Companies Want Partners as They Approach One of World's Biggest Healthcare Opportunities – China	1709
3.24	Progressive Reforms Shifting The Cancer Medicine Landscape in China.....	1711
3.25	Emerging Crowdfunding Schemes for Healthcare – Cancer Coverage for Pennies a Month in China	1712
3.26	Chinese Tourists to Japan Switch from Shopping Sprees to Medical Services.....	1715
3.27	Chinese Patients Head to India for Latest Drugs after Domestic Crackdown.....	1717
3.28	Chinese Hospitals Set to Sell Experimental Cell Therapies.....	1720
3.29	Sanofi, AZ, Lilly and More Won Business in China's Expanded Cut-Price Purchase Program	1723

3.30	Drug Makers including Roche and Novartis Slash Medicine Prices in China to Get on Reimbursement List	1724
3.31	Trade Deal Could Help China’s Biotech Upgrade, If Honored.....	1725
3.32	Why Chinese Biotech Companies Are Not for Faint-Hearted Investors.....	1727
3.33	China Has Become A CEO-Level Priority for MNC Pharma Companies: The Trend and The Implications.....	1730
3.34	2020 Begins with a Flurry of Biosimilar Activity in East Asian Markets	1733
3.35	16 Heavy-weight New Drug Expected to be Approved in China 2020	1735
3.36	CitiResearch – China at Inflection Point: Big Opportunity for MNCs, Domestic Leaders	1735
3.37	NRDL Updates Could Lead to Increased Access to Innovative Drugs in China	1737
3.38	How the Coronavirus Is Helping to Fix China’s Broken Healthcare System	1738
Chapter VI-4 Trends and Prospects in Pharma Outsourcing.....		1740
4.1	CMO/Manufacturing Outsourcing in China and Asia	1742
4.2	Will China Lose Its Cost-Competitiveness in Pharma Manufacturing?.....	1747
4.3	Overview – Listed Chinese Pharmaceutical CRO/CMDO Companies	1750
4.4	China Needs 30 Times Its Outsourcing Capacity to Meet Biologics Demand Created by Drug Pricing Reform: Wuxi Bio CEO.....	1753
4.5	China CDMO Market 2018-2021: The R&D Cost of New Drugs Continues to Rise While the Success Rate Decreases YoY.....	1754
4.6	Chinese CRO Market Set to Grow Substantially	1755
4.7	Trends and Prospects of Clinical Research in China	1758
4.8	SCORR Survey Expects Growing Clinical Trials in China	1764
4.9	Potential Compliance Risks in Clinical Research Outsourcing to China.....	1765
4.10	Regulatory Changes Position China as a Global Clinical Trial Destination	1769
4.11	How to Fulfill China’s Potential for Carrying Out Clinical Trials	1770
4.12	Asia: Preferred Destination For Clinical Trials.....	1771
4.13	Should You Look At China For Your Next Clinical Trial?	1776
4.14	China Isn’t Yet Ready to Conduct Clinical Trials for the Pharma Industry	1782
4.15	Why Asian CROs are Turning to the European Biotech Market	1783
4.16	Chinese Government Launch Support Program for Biopharma CRO and CMO Service Platforms	1787
4.17	New Roads to China for CROs and CMDOs.....	1788
4.18	Chinese Pharma CRO Industry to More Than Triple by 2025	1792
4.19	Outsourcing in China: How Far Can It Go?.....	1793
VOLUME 4 SALES & MARKETING, ENTRY STRATEGIES AND CASE STUDIES.....		1801
TABLE OF CONTENTS		1803
LIST OF TABLES		1813
LIST OF CHARTS.....		1814

TABLE OF ABBREVIATIONS.....	1815
PART VII PHARMACEUTICAL SALES, MARKETING AND DISTRIBUTION	1817
Chapter VII-1 History and Overview.....	1819
1.1 Pharmaceutical Sales and Distribution in China Before Early 1980s	1819
1.2 Breaking Up of the Old System	1820
1.3 The Present State of the Pharmaceutical Marketing, Sales and Distribution System in China – An Overview	1821
Chapter VII-2 Major Promotional Practices and Government Affairs	1828
2.1 National and Local Drug Reimbursement Lists	1828
2.2 Pricing of Drug Products	1833
2.3 Centralized Hospital Drug Purchase Tenders.....	1836
2.4 Product Launches.....	1839
2.5 Clinical Research	1840
2.6 Public Relations	1841
2.7 Lobbying for Industrial Policies and Regulations.....	1842
2.8 Building a Better Government Affairs Function in China.....	1842
2.9 Snapshot of Chinese Pharmaceutical Marketing and Digital Communication Channels.....	1849
Chapter VII-3 Marketing and Sales of Ethical Drugs in Urban Hospitals	1851
3.1 Mainstream Hospital Marketing and Sales Models	1851
3.2 The Hospital Drug Purchase Approval Process	1853
3.3 Hospital Drug Purchase Channels.....	1854
3.4 Hospital Marketing/Sales Organization and Execution	1855
3.5 Key Factors in Hospital Marketing and Sales.....	1856
3.6 Developing Effective Market Coverage and Sales Force Strategies in China	1858
3.7 Shifting from Network Marketing to Evidence Based Medicine in China	1861
3.8 More Chinese Pharma Cos Cuts Sales Force and Switch to Agency Sales.....	1863
Chapter VII-4 Marketing and Sales of Ethical Drugs through Urban Retail Pharmacies	1864
4.1 Channels of Retail Pharmacy Sales and Distribution.....	1864
4.2 Process and Key Components of Retail Pharmacy Sales.....	1865
4.3 Key Factors in Sales of Ethical Drugs through Retail Pharmacies	1865
4.4 Case in Point: Pfizer’s Retail Pharmacy Sales Efforts in China.....	1866
Chapter VII-5 Sales & Marketing of OTC Drug Products in Cities	1868
5.1 Channels of OTC Drug Sales.....	1868
5.2 Process and Key Components of OTC Drug Sales	1869
5.3 Key Factors in OTC Drug Sales	1870

Chapter VII-6 Sales, Marketing and Distribution of Drugs in the "Third Terminal Market"	1871
6.1 Pharmaceutical Sales & Distribution Channels to the "Third Terminal Market"	1871
6.2 Sales and Marketing Strategies for the "Third Terminal Market"	1872
6.3 Special Characteristics of the "Third Terminal Market"	1873
Chapter VII-7 Pharmaceutical Distribution	1875
7.1 Overview	1875
7.2 Important Regulatory Requirements on Pharmaceutical Distribution	1876
7.3 Pharmaceutical Distribution Channels in China	1877
7.4 GSP Requirements for Pharmaceutical Distributors	1880
7.5 Logistics in Pharmaceutical Distribution	1881
7.6 Opening of the Chinese Pharmaceutical Distribution Sector	1882
7.7 Recent Trends in Pharmaceutical Distribution	1884
7.8 Chinese Pharmaceutical Distribution Landscape and Models	1885
7.9 Building Distributor Channel Management Capabilities in China	1888
7.10 How the Distribution Challenge for Pharma is Going to Change in China	1893
7.11 The Challenges of Managing China's Highly Fragmented Distributor/Dealer Networks...	1896
7.12 Fitch: Further Consolidation of China's Drug Distribution Sector Inevitable	1898
7.13 Margin Pressure and Consolidation for China's Pharma Distributors	1899
7.14 New Two-Invoice System in Pharma Distribution Launched in 2017	1899
Chapter VII-8 e-Commerce and Digital Marketing Opportunities for Pharma Companies.....	1902
8.1 China Preparing for a Digitized Healthcare Landscape	1902
8.2 China to Experiment Internet Healthcare Expansion at Six Provincial Level Trial Sites	1903
8.3 Regulatory Developments for Telemedicine in China	1904
8.4 Kantar Health: Analysis of Digital Health in China.....	1906
8.5 Why China Will Capitalize On Groundbreaking Healthcare Solutions Before The West	1908
8.6 Balancing Act: China's Online Healthcare System Needs Both Innovation And Regulation	1909
8.7 China to Grow Big on e-Healthcare Data	1911
8.8 How Telemedicine Might Reshape Pharmacies in China	1914
8.9 How Tencent's Medical Ecosystem Is Shaping the Future of China's Healthcare.....	1916
8.10 IQVIA: Chinese Pharma Remain Over-dependent on MR Detailing with Minimal Spending on Digital Sales	1919
8.11 IQVIA's Digital Channel Survey Finds All Levels of Doctors Spend Similar Hours for e-Learning	1921
8.12 Can China's Tech Titans Succeed in Healthcare?	1922
8.13 The Hidden Challenges of China's Booming Medical AI Market	1925
8.14 Healthcare AI Patent Surge in China Reflects Momentum in MedTech Innovation.....	1928
8.15 China's Big Data Draws Pharmaceutical Companies Around the World.....	1929
8.16 COVID-19 Makes Digital Care the Norm in China.....	1929

PART VIII MARKET ENTRY STRATEGIES AND EXECUTION..... 1933**Chapter VIII-1 Preparations for a Market Entry Strategy.....1935**

1.1	The Need for a Market Entry Strategy	1935
1.2	Long Term Perspective	1935
1.3	Information Sources.....	1936
1.4	Getting Expert Help	1939
1.5	Market Research	1939
1.6	Selecting the Right Products	1940
1.7	China’s Evolving Pharma Partnering Landscape: The Right Partner Profile.....	1941
1.8	What Healthcare Companies Looking To Get Into China Must Know	1945
1.9	Five Elements to Consider When Choosing the Next Emerging Market to Enter	1947

Chapter VIII-2 Strategic Approaches for Market Entry.....1950

2.1	Direct Export of Finished Products.....	1950
2.2	Sino-foreign Joint Ventures.....	1952
2.3	Solely Foreign-owned Companies in China.....	1953
2.4	Licensing and Technology Transfer	1954
2.5	Merger & Acquisition (M&A)	1956

Chapter VIII-3 Execution of The Market Entry Strategy.....1958

3.1	Product Registration.....	1958
3.2	New Drug Clinical Trials and Patient Recruitment in China	1958
3.3	Latest Regulatory Developments on Ethical Review in Chinese Clinical Trials	1961
3.4	Selection of a Local Distributor for Imported Drugs	1962
3.5	Selection of a Chinese Partner for Joint Venture.....	1964
3.6	Product Launch	1965
3.7	Promotional Activities and Advertising	1965

Chapter VIII-4 Challenges and Realities for Operating in China.....1967

4.1	The Importance of Patience	1967
4.2	The Value of Relationship	1967
4.3	Dealing with Chinese Style Laws	1968
4.4	The Ethical Challenges of Doing Business in China’s Healthcare Economy	1968
4.5	Commercial Briberies Seen as a Leading Risk as Chinese and Foreign Governments Step Up Enforcements.....	1970
4.6	Behind China’s Corruption Crackdown: Whistleblowers	1973
4.7	Compliance in China: Ongoing Regulatory and Operational Challenges.....	1975
4.8	Staff Turnover and Talent Retention A Growing Problem	1978
4.9	Choosing Your General Manager for China.....	1980
4.10	Managing Sino-Foreign Joint Ventures in China	1983
4.11	Recruiting R&D Leaders in China and India	1988
4.12	Recruiting Medical Executives in China.....	1992

4.13	Managing Clinical Trials in Asia and China	1994
4.14	Resourcing Clinical Research Programs in China	1997
4.15	Protecting the Accuracy of Clinical Trial Data in China.....	2000
4.16	Why Your NDA Does Not Work For China.....	2002
4.17	How To Protect Trade Secrets In China When Employees Leave	2002
4.18	How to Protect Your Brand in China	2005
4.19	IFPMA and RDPAC Introduce New Code for Pharma Marketing Practices	2010
4.20	In Generic Drug Plants in China and India, Data Falsification Is Still A Problem	2011
PART IX MINI CASE STUDIES		2015
Chapter IX-1 China Experiences of Foreign Drug Companies		2017
1.1	Ranbaxy’s Successful Entry and Surprising Exit of the Chinese Market	2017
1.2	Zuellig Pharma China/Cardinal Health China – A One-Time Successful Case and Business Model for China’s Pharmaceutical Distribution Sector with A Disappointing End	2019
1.3	West Pharmaceutical Services – Tapping into China’s Growing Healthcare Industry.....	2023
1.4	Novo Nordisk China – Focusing on Diabetes and Ample Room for Growth.....	2025
1.5	Abbott Succeeds in China by Focusing on Nutrition Business.....	2030
1.6	Bayer’s Big Bet on China	2031
1.7	Bayer Troubled by Integration of Acquired OTC Business in China.....	2034
1.8	Roche’s Unique, Global Strategy for China.....	2035
1.9	Helping Establish Private Health Insurance for Cancer in China – A Roche Story	2041
1.10	A Decade Old Drug Launch in China with Important Insights Today – BMS’s Experience with Baraclude in China.....	2042
1.11	Ipsen Outlines Strategies for Continued Growth in China – The Success Story of a Mid-size Company	2047
1.12	SciClone Pharmaceuticals: Building a Product Portfolio Optimized for China’s Evolving Pharmaceutical Market.....	2049
1.13	Leveraging U.S. Resources and Chinese Partnership for Drug Development and Commercialization	2054
1.14	Why Did One of the World’s Largest Generic Drug Makers Exit China?	2057
1.15	CleveXel’s Collaboration with Guilin Pharma for Development of Artesunate Injection ..	2060
1.16	Lessons from Glaxosmithkline’s Record \$492 Million Bribery Fine in China.....	2063
1.17	One Multinational’s Lessons Learned in China	2065
1.18	MSD and Nanjing Simcere Set to Go Their Own Ways	2067
1.19	Merck Finds Shortcut for Anticancer Keytruda into China via Medical Tourism	2069
1.20	Merck’s Gardasil Preps for Head-to-head with GlaxoSmithKline’s Cervarix in China, with Big Sales Targets Ahead.....	2070
1.21	Pfizer Builds Viagra Success in China Despite Fierce Competition and Generics	2072
1.22	Pfizer Makes Bold Moves to Maximize China Business under New Leadership	2074
1.23	Eli Lilly Launches LEAP to Expand Lower Tier Market Access in China	2075
1.24	Sanofi to Center Its China Business Strategy on Primary Healthcare	2076
1.25	Sanofi CEO Pledges More Investment, R&D Facility, 16 New Drugs and Digital Healthcare for	

China	2077
1.26 Ten Years and \$100M+ Later, GSK Shuttles A China R&D Site amid Reorganization	2079
1.27 GSK’s Digital Strategies for Reaching New Buyers in China	2080
1.28 GSK CEO Pledges to Learn from Mistakes in the Chinese Vaccine Market	2082
1.29 China: AstraZeneca’s New Engine for Growth and Innovation	2083
1.30 AstraZeneca Markets an Herbal-Based Remedy to Expand in China	2089
1.31 Eli Lilly Spins Off Non-core Assets to Chinese Companies	2092
1.32 Boehringer Ingelheim Increases Focus on Chinese Rural Areas and Bets on CDMO Market 2094	
1.33 Gilead Sciences Takes Off in China with Commitment to Cure Hepatitis	2096
1.34 Despite Strong Albumin Sales, CSL Complains of Barriers in China Business	2098
1.35 Eisai Gives Chinese Doctors and Patients Upper Hand against Cancer, Serious Illnesses .	2099
1.36 Kobayashi Pharma: China Business Growth without China Presence	2100
1.37 American Drug Entrepreneur Finds His Dream in Beijing	2102
1.38 Exploring Ways to Establish Presence in China as Part of APAC Region Push: Lupin Pharma 2103	
1.39 GNC: China Strategy Hits Tariff Shoals	2104
1.40 China Gives Merck, BMS Cold Shoulder On Reimbursement List as PD-1 Battle Enters New Phase	2107
1.41 Astrazeneca Rounds Out Stellar China Year – And Beats Roche To The Punch – with Imfinzi Lung Cancer Nod	2109
1.42 Xian Janssen: Embrace Better Future with New Solutions	2111
1.43 Takeda Aspires to Become A Top Ten MNC Pharma Co. in China	2113
1.44 Novartis Eyes Registration of 50 New Drugs in China Before 2023	2114
Chapter IX-2 R&D and Outsourcing Case Studies.....	2116
2.1 Birth of A New Novel Anticancer, Made in China	2116
2.2 Huya Bioscience – Tapping into China for Novel Drug Candidates	2117
2.3 BeiGene Strives to Become China’s Genentech	2119
2.4 Two Emerging Companies Leverage the Strength of Both China and the U.S. for Growth	2121
2.5 Chinese Innovation: BGI’s Code for Success	2124
2.6 China Learns the Lesson of Vaccine R&D Bubble – The Story of Chongqing Brewery’s in Development of Its Novel HepB Vaccine	2128
2.7 Research Partnership between BMS and Simcere: The Right Chemistry amid A Global Paradim Shift of Drug R&D?	
2.8 China’s Academic “Black Market” Fooled Canadian Medical Journal	2135
2.9 A Setback for Chinese Drug R&D	2137
2.10 USFDA Found China Data Irregularities for Key Study of Pfizer and BMS’s Eliquis	2140
2.11 How Chinese Suppliers to Global Drug Firms Hide Bad Test Results	2142
2.12 Chinese Companies Make Progress on New Drugs from TCM Herbs	2143
2.13 A Better Pill from China – Chinese Pharma Firms Target the Global Market	2145
2.14 Novartis CEO on Why the Firm Opened a Major R&D Facility in China	2146

2.15	Pfizer to Use GE's Mobile Biotech Factory to Make Next-Generation Drugs in China.....	2149
2.16	Cross-sector Synergy: China Innovation at Merck	2150
	Chapter IX-3 Human Resource Management Case Studies.....	2157
3.1	AstraZeneca China: Continued Mission on People	2157
3.2	Novartis China: The Learning Strategy	2158
3.3	Trends in Managing Pharmaceutical R&D and Medical Affairs Professionals	2160
3.4	Sanofi Turns to AI to Cut Chinese Recruitment Churn.....	2164
	Chapter IX-4 Legal Case Studies: IPR/Counterfeits/AML/Others.....	2167
4.1	Sankyo vs. Beijing Wansheng: First Lawsuit over Process Patent for Preparing Pharmaceutical Composites.....	2167
4.2	Pfizer vs. 12 Local Drug Companies: Landmark Lawsuit over Viagra Patent.....	2168
4.3	Eli Lilly vs. Beijing Ganli – Battle over Insulin	2170
4.4	Boehringer Ingelheim vs. Chaitai Tianqing over Tiotropium Bromide	2171
4.5	Legal Battle between Sanofi and Jiangsu Hengrui over Docetaxel	2172
4.6	Merck vs. Henan Topfond over Chinese Patent for Finasteride.....	2173
4.7	Aurisco Challenges Gilead's Chinese Patent for Viread	2173
4.8	Fake Drug Sting Operation – GSK Experience	2175
4.9	Legal and Ethical Implications of ELAD Clinical Trial Death.....	2176
4.10	Ruling over Liabilities of Distributors and Hospital in Fake Armillarisni-A Inj. Case.....	2178
4.11	Novartis Sued and Challenged for Deaths Linked to Its Hepatitis B Drug Sebivo	2179
4.12	Illegal and Off-Label Use of Roche's Avastin Led to Serious ADRs in Shanghai.....	2180
4.13	Off-label Use of Bayer Healthcare's XARELTO under Challenge in China	2182
4.14	Review of the 11-Year Trademark Fight between Roche and Southwest Pharma	2183
4.15	Merck & Co. Loses Trademark Fight against Tianjin Zhongxin Pharma	2186
4.16	Pfizer Loses Final Battle for Chinese Trademark of Viagra	2187
4.17	Johnson & Johnson Loses Trademark Lawsuit against SAIC's Trademark Review Board	2187
4.18	Bayer Settles Six-Year Trademark Infringement Lawsuit with Henan Baier Pharma	2188
4.19	The Rio Tinto Case Lays New Ground for PR of Foreign Companies in China	2188
4.20	Siemens Sued in the U.S. by Former Employee over Bribes in China	2192
4.21	China's Anti-Japanese Boycott Extended to Pharmaceuticals	2193
4.22	The Impact of Restricted Data-flows on China's Digital Healthcare Solutions.....	2194
4.23	SIPO Invalidates Gilead Sciences' Viread Patent in China.....	2196
4.24	China Rejects Patent for Gilead's Expensive Hepatitis C Drug.....	2197
4.25	Gilead's Key Sovaldi Patent Claims Partially Invalidated in China	2198
4.26	MSF Challenges Gilead's HCV Patent Application in China	2199
4.27	Bayer Loses Avelox (Moxifloxacin) Patent Battle in China	2201
4.28	Eli Lilly vs. Changzhou Watson: China's Supreme Court Sides with Local Firm After Court Designated Technical Investigations	2201
4.29	Three Supreme Court Cases on Pharmaceutical Patents.....	2202
4.30	Novartis Lost Gleevec Infringement Lawsuit in China against Jiangsu Hansoh Pharma ...	2205
4.31	Review of China's High Profile Investigation of GSK for Corruption	2205

4.32	GSK Sued by Couple It Hired to Investigate Whistleblower	2221
4.33	The “Dignified” Drug-Dealer – A Case for Thought over Patient Access to Medicines, Parallel Import, Compulsory Licensing and Drug Pricing	2222
4.34	Pfizer Fined by Shanghai Government for Irregular Pharmacy Display Fees	2225
4.35	Shanghai Fines Novo Nordisk CNY 2.6 Mln for Distributor License Violation.....	2226
4.36	Shanghai AIC Hits Foreign Firms with Fines for Compliance Violations	2226
4.37	Other Anti-Monopoly Enforcement Cases.....	2228
4.38	Chinese Antitrust Authority Imposes Maximum Fine In Rare Abuse Of Collective Dominance Case	2237
4.39	FCPA Compliance Cases and Other Related Foreign Lawsuits	2239
4.40	China’s Conditional Approval of Bayer’s Acquisition of Monsanto: Lessons for Future Merger Cases in China	2243
4.41	Bayer Pharma Hit with China-attributed Malware.....	2245
4.42	Who Owns the Coronavirus Cure? China’s Move to Patent Gilead’s Experimental Drug for The Novel Virus Could Lead to Legal Wrangle	2246
4.43	The Case of Remdesivir from the Chinese Perspective – Patent Applications on Inventions for Pharmaceutical Use	2248
4.44	U.S. Senate Report Accuses China of Technology Theft	2250
4.45	Beijing High Rejects Novartis’ Trademark Registration of "Alcon"	2250
4.46	Cardinal Health Settles with SEC for China-linked FCPA Allegations	2251
Chapter IX-5 Success and Failure Stories of Domestic Companies.....		2255
5.1	BGI: The Kung Fu Panda of the Genomic World	2255
5.2	3SBio – The Success Story of a Chinese Biogeneric Company	2258
5.3	Zhejiang Hisun Pharmaceutical Ltd. – A Showcase for International Business Transformation of Chinese Pharma Companies.....	2261
5.4	Tongjitang Chinese Medicines Company – The Tale of a Fallen Wall Street Darling and One of the Earliest "China Concept" Drug Stocks.....	2266
5.5	GenePharma – The Story of a Small Niche Chinese Biotech Company.....	2268
5.6	Luqa Pharmaceuticals – Expatriate-founded Chinese Pharma Startup with a Strategy of Tailoring Products for China through Partnerships	2270
5.7	Fosun Pharma Expands Global Business Via M&As and Innovative R&D	2273
5.8	Backed by China, Ambrx No Longer Dependent on Partnerships with MNCs	2277
5.9	BeyondSpring Pharma: Communicating Across US-China Lines	2279
5.10	EOC Pharma Strives to Bring Potential Oncology Blockbusters to China	2280
5.11	Hua Medicine Mulls HK IPO as Diabetes Drug Enters Crucial Clinical Trial Phase	2281
5.12	China’s Tech Tycoons’ Healthcare Dreams Aren’t Coming True.....	2282
5.13	Ali Health’s Reversal of Fortune on the Back of Soaring Online Pharmacy Sales	2285
5.14	Dendreon Figures Provenge Growth, Infrastructure Can Pave Its Way into CAR-T	2288
5.15	China’s Biopharmas Buffeted by Clashing Market Dynamics.....	2290
5.16	Top Chinese Pharma Tycoons Advance on Forbes China Rich List in 2018	2294
5.17	42 Chinese Pharma Billionaires Made the Hurun Global Rich List 2019.....	2295

5.18	BeiGene: The Poster Child Of China’s Booming Biopharma Market	2297
5.19	Pre-profit BeiGene Produced Two of the World’s Highest Paid Pharma CEOs	2300
5.20	Can Alibaba Health Information Technology Transform China’s Pharma Industry?.....	2301
5.21	Yaobili Set to Change China’s Pharmaceutical Industry with New Model.....	2305
CHAPTER IX-6 Creative Alliances among Pharma cos and Insurers		2307
6.1	Roche to Expand Cancer Sales through Joint Supplemental Insurance with Swiss RE.....	2307
6.2	Pfizer China, PICC and MediTrust Co-launched China’s First Pay-for-Performance Oncology Insurance.....	2308
6.3	Insurer Manulife-Sinochem Inks Deal with Healthcare Platform 111 Inc.	2309
6.4	Tsumura to Penetrate China’s Herbal Drug Market with the Help of Ping An Insurance	2310
CHAPTER IX-7 Alliances between Pharma and e-commerce/IT Cos		2313
7.1	GSK, AliHealth Join Hands to Build Vaccine Promotion Channel with Initial Focus on Cervarix	2313
7.2	GSK Ties Up with JD to Offer Integrated Online Medical Services	2314
7.3	Reckitt Benckiser, Alibaba Join Hands to Market Quality Health Products to China	2314
7.4	Merck and Alibaba Health Announce Collaboration to Develop Patient-Centric Digital Services in China.....	2315
7.5	Allergan and AliHealth to Launch Digital Platform for Medical Aesthetics Market	2317
7.6	Lilly China and Microsoft Enter Digital Health Partnership Using AI to Empower Medical Innovation in China	2318
7.7	Pfizer Eyes Huge Potential in Online Sales of Its Health Products in China.....	2319
7.8	Novartis and Tencent Enter Strategic Partnership for Digital Medicine	2321
7.9	AstraZeneca CEO Gambles on China’s Internet of Things	2322
7.10	Ping An Good Doctor Ties Up with Jointown Pharma to Enpower Primary Healthcare	2323
7.11	Three Key Takeaways From BeiGene’s CEO	2325
APPENDICES		2329
Appendix I Drug Administration Law of the PRC		2331
Appendix II Regulations for Implementation of Drug Administration Law.....		2357
Appendix III Regulations on Administrative Protection for Pharmaceuticals		2376
Appendix IV The Provisions for Registration of Drug Products.....		2380
Appendix V Special Review and Approval Procedure for Drug Registration.....		2407
Appendix VI Administrative Reconsideration Measures.....		2413
Appendix VII Provisions for Drug Insert Sheets and Labels.....		2418
Appendix VIII The Provisions for Control of Drug Manufacture.....		2423
Appendix IX Provisions for CONTROL of Drug Distribution.....		2444
Appendix X Provisions for Drug Advertisement Examination.....		2450

LIST OF TABLES

Table 1.1 China’s state and private shares of fixed asset investment (FAI) 2017-2019 ..	59
Table 1.2 Income Distribution among the Chinese Population	99
Table 1.3 Number of Pharmaceutical Businesses in China 1997-2019	141
Table 1.4 Segmentation of Global API Companies 2017	149
Table 1.5 Country Share of Established API Providers Globally 2017	150
Table 1.6 Growth of the Chinese API/Bulk Drug Sector 2002-2019	151
Table 1.7 Growth of the Chinese API/Bulk Drug Sector 2002-2019	151
Table 1.8 Revenue in Chinese API Industry 2012-2017.....	152
Table 1.9 Chinese Foreign Trade of Biochemical Drugs 2007-2018 (US\$ mln).....	167
Table 1.10 Vaccine IND Applications and NDAs Accepted by CDE 2019.....	168
Table 1.11 # of Accepted Biological Drugs Applications by CDE 2008-2017.....	169
Table 1.12 Biologic Applications Accepted by CDE 2013-2017: Domestic vs. Import	169
Table 1.13 Type of Biologic Applications Accepted by CDE in 2017	170
Table 1.14 Accepted New Biologic Applications by Dosage Form 2017.....	170
Table 1.15 Accepted New Biologic Applications by Class 2017.....	170
Table 1.16 Top 15 Companies by CDE Accepted Biologic Applications 2017.....	171
Table 1.17 Top 9 Cos by # of CDE Accepted New Biologic Applications 2017.....	171
Table 1.18 Status of CDE Accepted Biologic Applications in 2017.....	172
Table 1.19 Classification of Approved Biological Applications in 2017.....	172
Table 1.20 CDE Acceptance Time of New Biologic Approvals 2017.....	173
Table 1.21 China Biologic Companies Listed in Hongkong Stock Exchange 2019	173
Table 1.22 Financing of Chinese Biologic Companies 2019.....	173
Table 1.23 Status of Chinese Biopharma Companies in SSE Star Market 2020.....	174
Table 1.24 Number of Pharma Distribution License Holders 2013-2018	186
Table 1.25 Structure of Chinese Retail Pharmacy Sector 2006-2018.....	186
Table 1.26 Chinese Drug Distribution Industry Performance 2011-2017	187
Table 1.27 Chinese Pharma Distributor Sales by Terminal Markets 2016-2017.....	187

Table 1.28 Composition of Chinese Pharmaceutical Distributor Sales in 2016	188
Table 1.29 Chinese Retail Pharmacy Market Segmentation in 2017.....	188
Table 1.30 Chinese Pharma Distributor Segmentation by Ownership 2017.....	189
Table 1.31 Regional Chinese Pharma Distribution Sales in 2017.....	189
Table 1.32 Regional Pharmaceutical Distributor Sales Structure 2016-2017.....	190
Table 1.33 E-Commerce Composition of Chinese Drug Distributor Sales 2017.....	192
Table 1.34 Composition of B2B Sales by Chinese Drug Distributors 2016-2017.....	192
Table 135 Composition of B2C Sales by Chinese Drug Distributors 2016-2017.....	192
Table 1.36 Top 20 Listed Chinese Pharma Companies by R&D Spending 3Qs/2019 ..	199
Table 1.37 R&D Centers of RDPAC Members in China	203
Table 1.38 Share of Chinese Clinical Trials by Region 2019	216
Table 1.39 Selected Outbound Sino-Foreign Licensing Deals 2015 – 2016.....	217
Table 1.40 Out-licensing Deals of Novel Drugs Originated in China 2011-2017	218
Table 1.41 Out-licensing Deals of Chinese Pharma Companies 2018.....	219
Table 1.42 Top Ten A Share-Listed Chinese Pharma Companies by Revenue in 2019.	228
Table 1.43 21 Chinese Pharma Cos in Fortune China 500 in 2019	229
Table 1.44 Top 20 Listed Chinese Pharma Cos by R&D Investment H1/2019	230
Table 1.45 Top 15 China Pharma Companies by R&D Spending 2017-H1/2019.....	231
Table 1.46 Top 20 Chinese Non-State-Controlled Healthcare Cos 2020 by Hurun.....	232
Table 1.47 Top 20 Chinese OTC Drug Producers 2019.....	233
Table 1.48 Chinese Companies in Top 500 China Fortune 2020.....	234
Table 1.49 Top Ten Chinese Chemical Drug Companies by Sales in 2018.....	234
Table 1.50 Top Ten Chinese Biologic Companies by Sales in 2018.....	235
Table 1.51 Top Ten Chinese CRO/CMDO Companies by Sales in 2018	235
Table 1.52 R&D Spending of A-Share Listed Chinese MedPharm Companies 2016-2018	235
Table 1.53 Top 15 Most Innovative A-Share Listed MedPharm Cos 2018	236
Table 1.54 Top 100 Most Innovative A-Share Listed MedPharm Cos 2018 (1).....	236
Table 1.55 Top 100 Most Innovative A-Share Listed MedPharm Cos 2018 (2).....	237

Table 1.56 Top 100 A-Share Listed MedPharm Cos by R&D Spending 2018 (3)	237
Table 1.57 Capitalization of Top 100 Most Innovative A-Share Listed MedPharm Cos 2016-2018	238
Table 1.58 Top 20 Pharma Distribution Companies 2019	238
Table 1.59 Top Ten Chinese Retail Pharmacy Chains by Overall Strength in 2018.....	239
Table 1.60 Top Ten Retail Pharmacy Chains by Direct Operation Strength in 2018	239
Table 1.61 Table 1.56 Pharma Foreign I Companies 2018-2019.....	240
Table 1.62 Top 25 Listed Chinese CRO/CDMO Companies in 2019	240
Table 1.63 New Foreign Investments in Chinese Pharma Industry 2013	266
Table 1.64 First Ten Sino-Foreign Pharmaceutical Joint Ventures in China	266
Table 1.65 Foreign Investment in the Chinese Pharmaceutical Industry in the 1990s ..	267
Table 1.66 Pharma Foreign Investments in China between 2000 and 2006	267
Table 1.67 Top 10 Pharma MNCs in China by Investment	269
Table 1.68 Chinese Hospital Drug Market Size 2013-2018	290
Table 1.69 Chinese Rx Drug Market by Terminal Market 2018	291
Table 1.70 Growth of Chinese Retail Pharmacy Sales 2000-2019	302
Table 1.71 Shares of Retail Drug Sales Channels 2001-2019	303
Table 1.72 Chinese Biopharma Market 2013-2019 (CNY bln).....	312
Table 1.73 Top 10 TCs of the Chinese Biopharma Market 2016.....	312
Table 1.74 Top 10 Biopharma Drugs in China 2013-2016	313
Table 1.75 Top Ten Chinese Biopharma Companies 2013-2016.....	313
Table 1.76 Chinese Sales of SIP Pediatric Vaccines 2006-2016.....	321
Table 1.77 Top 10 Biologics by Batch Release Sales in China 2014-2018.....	322
Table 1.78 Chinese Vaccine Consumption 2005-2020E.....	325
Table 1.79 Compound Vaccines with No Local Production in China	326
Table 1.80 Polyvalent Vaccines with No Local Production in China	326
Table 1.81 Therapeutic Vaccines Launched Outside China.....	327
Table 1.82 Application Status of Therapeutic Vaccines in China 2017	328
Table 1.83 Chinese Foreign Trade of Medicines and Health Products in 2018 (1).....	348

Table 1.84 Chinese Foreign Trade of Medicines and Health Products in 2018 (2)	348
Table 1.85 Chinese Import of Medicines 2014-3Qs/2019	349
Table 1.86 Chinese Monthly Import of Medicines in 2019	349
Table 1.87 # of ANDA Approvals Issued by USFDA to Chinese Cos 1974-2019	351
Table 2.1 Improvement of Medical Provision in China	357
Table 2.2 Comparisons of Healthcare Provision by China vs. Other Countries (1)	358
Table 2.3 Comparisons of Healthcare Provision by China vs. Other Countries (2)	359
Table 2.4 Comparisons of Healthcare Provision by China vs. Other Countries (3)	359
Table 2.5 Birth, Death and Population Natural Growth Rate.....	360
Table 2.6 Rising Life Expectancy of the Chinese Population.....	361
Table 2.7 Composition of the Chinese Population by Urban/Rural Division and Sex ..	363
Table 2.8 Composition of the Chinese Population by Age	364
Table 2.9 Composition of the Chinese Population by Education.....	364
Table 2.10 Medical Institutions and Its Inpatient Beds by Type and Ownership.....	371
Table 2.11 Healthcare Personnel by Professional Categories in China 2010-2019	372
Table 2.12 Healthcare Personnel by Medical Institute Type and Ownership	373
Table 2.13 Outpatient Visits and Inpatients by Medical Institution Type 2017-2019....	375
Table 2.14 Workload of Chinese Physicians by Hospital Type 2016-2019	375
Table 2.15 Occupancy Rate and Average Days of Hospitalization by Hospital Type 2016-2019.....	376
Table 2.16 Medical Service Statistical Summary of Township Health Centers.....	376
Table 2.17 Number of Village Clinics and Healthcare Professionals	377
Table 2.18 Statistical Summary of Community Healthcare Service Centers.....	377
Table 2.19 Statistical Summary of Community Healthcare Service Stations	378
Table 2.20 TCM Medical Institutions and its Inpatient Beds by Type and Ownership .	378
Table 2.21 Outpatient Visits and Inpatients in TCM Medical Institutions by Type in 2017-2019.....	379
Table 2.22 Share of Primary Healthcare Facilities with TCM Services (%)	379
Table 2.23 TCM Healthcare Professionals in China	380

Table 2.24 Structure of Outpatient and Inpatient Medical Expenditures 2018-2019	381
Table 2.25 Medical Institutions by Specialties and Affiliations	396
Table 2.26 Inpatient Beds of Medical Institutions by Specialties and Affiliations.....	397
Table 2.27 Medical Institutions by Ownership Type	398
Table 2.28 Inpatient Beds of Medical Institutions by Ownership Type.....	398
Table 2.29 Inpatient Beds of Medical Institutions by Hospital Grade.....	398
Table 2.30 Number of Medical Institutions by Grade in 2012	399
Table 2.31 Number of Medical Institutions by Grade 2013-2019	399
Table 2.32 Number Growth (%) of Medical Institutions by Grade 2013-2019.....	399
Table 2.33 Regional Population Distribution in China 1990-2018.....	400
Table 2.34 Regional Distribution of Medical Institutions in Q1/2020	401
Table 2.35 Regional Distribution of Medical Institutions and Inpatient Beds in 2018 .	402
Table 2.36 Regional Distribution of Healthcare Professionals in 2018.....	403
Table 2.37 Distribution of Inpatient Beds by Medical Specialty 2005-2012	404
Table 2.38 Distribution of Physicians by Medical Specialty 2000-2012.....	405
Table 2.39 Healthcare Personnel in China 1990-2018.....	405
Table 2.40 Healthcare Personnel in China 2010-2019.....	406
Table 2.41 Distribution of Healthcare Personnel in Cities and Counties 1990-2018	406
Table 2.42 Key Healthcare Reform Goals for 2017	428
Table 2.43 Key Healthcare Reform Goals by 2020	429
Table 2.44 Overview of the Chinese BMI System in 2019 (1).....	438
Table 2.45 Overview of the Chinese BMI System in 2019 (2).....	439
Table 2.46 BMI System Financial Performance Q1/2020 (Unit: CNY mln).....	439
Table 2.47 Makeup of Healthcare Expenditures in China between 1980 and 2019	441
Table 2.48 Financial Overview of the Chinese BMI System in 2019	445
Table 2.49 BMI Claims and Inpatient Expenses at Different Hospital Levels 2012-2018	445
Table 2.50 Enrollment Structure of UEBMI Program by Employment Status 2012-2019	446

Table 2.51 Financial Performance of URRBMI Program 2012-2018	446
Table 2.52 Overview of Chinese UEBMI System 2018	448
Table 2.53 Overview of Chinese URBMI System 2018	451
Table 2.54 Overview of Chinese BMI System in 2019.....	461
Table 2.55 Financial Overview of the Chinese BMI System in 2019.....	462
Table 2.56 Enrollment Structure of UEBMI Program by Employer Type 2017-2019 ..	462
Table 2.57 Enrollment Structure of UEBMI Program by Employment Status 2010-2019	462
Table 2.58 Claims and Outpatient Visits of UEBMI Program 2012-2019.....	462
Table 2.59 Average Expense and BMI Payout Per Inpatient of UEBMI Program 2012-2019.....	463
Table 2.60 UEBMI Reimbursement of Inpatient Expenses by Hospital Levels 2019...	463
Table 2.61 Shares of Inpatient Visits at Different Levels of Hospitals 2012-2018.....	463
Table 2.62 Share of Inpatient Expenditures in Total by Hospital Levels 2017-2018.....	463
Table 2.63 Enrollment of Urban Residents in URBMI Programs 2019.....	464
Table 2.64 Financial Performance of URBMI Program 2009-2019	464
Table 2.65 BMI Claims and Inpatient Expenses at Different Hospital Levels 2012-2019	464
Table 2.66 URBMI Reimbursement of Inpatient Expenses by Hospital Levels 2019...	465
Table 2.67 URBMI Reimbursement of Inpatient Expenses by Hospital Levels 2018...	465
Table 2.68 No. of Reimbursable Drugs under the NRDL 2000 – 2019	485
Table 3.1 Growth of Drug Consumption in China 2001-2019.....	565
Table 3.2 Growth of Healthcare Expenditures in China 1980-2019	566
Table 3.3 Share of Per Capita Drug Expenditures in Healthcare	568
Table 3.4 Leading Diseases by Two-Week Morbidity in 2013	574
Table 3.5 Leading Disease Categories by Two-Week Morbidity in 2013 vs. 2008	575
Table 3.6 Leading Diseases by Two-week Morbidity in 2003	576
Table 3.7 Leading Diseases by Two-week Morbidity in 2008.....	577
Table 3.8 Morbidity Rate of Chronic Diseases in 2003 and 2008	577

Table 3.9 Trend of Leading 10 Diseases among Inpatients of Urban Hospitals.....	578
Table 3.10 Leading 10 Diseases among Inpatients of County Level Hospitals.....	579
Table 3.11 Leading Casues of Death and Composition in Urban Areas 2015.....	580
Table 3.12 Leading Causes of Death in Certain Regions of China in 2012	581
Table 3.13 Leading Causes of Death among Chinese Males in 2012.....	581
Table 3.14 Leading Causes of Death among Chinese Females in 2012	582
Table 3.15 Chinese Cancer Prevalence and Patterns	608
Table 3.16 Regional Distribution of Chinese Cancer Patients and Deaths.....	608
Table 3.17 Top 5 Cancers by Morbidity Rate 2017 (Male vs. Female).....	609
Table 3.18 Top 5 Cancers by Morbidity Rate in Urban Areas (Male vs. Female).....	609
Table 3.19 Top 5 Cancers by Morbidity Rate in Countryside (Male vs. Female)	609
Table 3.20 Five-Year Cancer Prevalence in China (2011).....	609
Table 3.21 Breakdown of Cancer Survival Patients: Age Groups (2011).....	610
Table 3.22 Breakdown of Cancer Survival Patients: Male vs. Female (2011)	611
Table 3.23 Breakdown of Cancer Survival Patients: Urban vs. Rural (2011)	611
Table 3.24 Composition of Medical Care Providers in China 1950-2019.....	624
Table 3.25 Composition of Medical Care Providers in China 2019-2020.....	625
Table 3.26 Number of Outpatient Visits and Inpatients in Medical Institutions 1980-2019	625
Table 3.27 Outpatient Visits & Inpatients by Medical Institution Type in 2016-2018 ..	627
Table 3.28 Outpatient Visits and Inpatients by Medical Institution Type in Q1/2016...	627
Table 3.29 Regional Distribution of Outpatient Visits and Inpatients in Q1/2016	628
Table 3.30 No.of Outpatient Visits and Inpatients by Medical Specialties in 2012	629
Table 3.31 No. of Outpatient & Emergencies Visits by Medical Specialties 2011-2012	629
Table 3.32 Average Days of Hospitalization 1985-2019	630
Table 3.33 Occupancy Rate and Average Days of Hospitalization by Hospital Type 2016-2019.....	630
Table 3.34 Regional Distribution of Medical Institutions and Inpatient Beds in 2016 ..	631

Table 3.35 Overall Healthcare Expenditures in China 2013-2019.....	631
Table 3.36 Composition of Healthcare Expenditures in China 2013-2019.....	632
Table 3.37 Structure of Outpatient and Inpatient Medical Expenditures 2015-2016.....	632
Table 3.38 Structure of Outpatient and Inpatient Medical Expenditures 2017-2018.....	632
Table 3.39 Structure of Outpatient and Inpatient Medical Expenditures 2018-2019.....	633
Table 3.40 Outpatient & Inpatient Medical Expenditures by Hospital Level H1/2020 .	633
Table 3.41 Top 10 Drug Suppliers to Chinese Hospitals MAT Q1/2020	634
Table 3.42 Top 10 TCs by Sales in Chinese Hospitals MAT Q1/2020	635
Table 3.43 Top 10 Drug Products by Sales in Chinese Hospitals Q1/2020	635
Table 3.44 Drug Sales Value in China Hospitals 2015-2019	636
Table 3.45 Drug Sales Value by Tiered in China Hospitals 2017-2019.....	636
Table 3.46 Drug Sales Value by Tiered in China Hospitals 2019: MNCs vs. Domestic	636
Table 3.47 Top 10 Drug Suppliers to Chinese Hospitals 2019	637
Table 3.48 Top 10 Drug Products in Chinese Hospitals 2019.....	637
Table 3.49 Top 10 TCs in Chinese Hospitals 2019	638
Table 3.50 China's Public Hospital Drug Markets 2010-2019	639
Table 3.51 Segmentation of Chinese Public Hospital Drug Sales 2011-2019	639
Table 3.52 Growth of Chinese Public Hospital Drug Sales by Channel 2017-2019.....	639
Table 3.53 Top 20 TCs by Drug Sales in Chinese Public Medical Institutions 2019	640
Table 3.54 Top 20 Drug Brands by Sales in Public Medical Institutions 2019	641
Table 3.55 Chinese Urban Rep Hospital Drug Market 2012-2019	642
Table 3.56 Chinese Urban Rep Hospital Drug Market Share by TCs 2012-2019	642
Table 3.57 Top 20 Drug Suppliers in Chinese Rep Urban Hospitals 2019	642
Table 3.58 Top Pharma Player in Ten TCs of Chinese Urban Rep Hospitals 2019	643
Table 3.59 Top 20 Drug Products in Chinese Urban Rep Hospitals 2019	643
Table 3.60 # of Drug Products in Level 2 & 3 Chinese Hospitals 2014-2018.....	644
Table 3.61 # of Drug Products in Chinese Hospitals by TC 2014 vs. 2018.....	644
Table 3.62 Hospital Drug Consumption Value Growth by Level 2014-2018	645

Table 3.63 Share of Dosage Forms by Drug Consumption Value 2014-2018.....	645
Table 3.64 Share of Dosage Forms by Use Frequency 2014-2018.....	645
Table 3.65 Top 10 Drugs by Hospital Consumption Value Share 2018.....	646
Table 3.66 Top 10 Systemic Anti-infectives by Hospital Consumption Value Share 2018	647
Table 3.67 Top 10 Oncology & Immuno-Regulatory Agents by Hospital Consumption Value 2018	647
Table 3.68 Top 10 Digestive system & Metabolic Drugs by Consumption Value Share 2018.....	647
Table 3.69 Top 10 Blood & Blood Making System Drugs by Hospital Consumption Value 2018.....	648
Table 3.70 Top 10 Nervous System Drugs by Hospital Consumption Value 2018	648
Table 3.71 Top 10 Cardiovascular System Drugs by Hospital Consumption Value 2018	648
Table 3.72 Top 10 Respiratory System Drugs by Hospital Consumption Value 2018 ..	649
Table 3.73 Top 10 Drugs by Hospital Use Frequency Share 2018	649
Table 3.74 Top 10 Pharma Cos by Hospital Drug Purchase Value 2018.....	650
Table 3.75 Top 10 Pharma Cos by Hospital Drug Purchase Volume 2018.....	650
Table 3.76 Number and Distribution of Medical Facilities in China.....	651
Table 3.77 Chinese County Public Hospital Drug Market 2011- 2019	651
Table 3.78 Share of County Hospitals in Total Public Hospital Drug Sales 2011-2019	651
Table 3.79 Chemical Drug Sales by TCs in Chinese County Public Hospitals 2019	652
Table 3.80 Top 20 Chemical Drug Brands by Sales Value in Chinese County Public Hospitals 2019	652
Table 3.81 MNC Market Share in Urban and County Level Hospitals 2009-2017.....	654
Table 3.82 Drug Consumption by Urban Public CHCs 2010-2018.....	655
Table 3.83 Drug Sales of Chinese Public Primary Healthcare Facilities 2011-2019.....	656
Table 3.84 Drug Sales Segmentation of Chinese Public Primary Healthcare Facilities 2011-2019	656
Table 3.85 Drug Consumption by Urban Public CHCs 2010-2019.....	657

Table 3.86 Share of Urban Public CHCs in Total Public Primary Healthcare Drug Consumption 2011-2019	657
Table 3.87 TC Composition of Urban Public CHC Chemical Drug Sales 2016.....	657
Table 3.88 TC Composition of Urban Public CHC FTCM Sales 2016	658
Table 3.89 Top 20 Chemical Drugs by Sale Value in Urban Public CHCs 2016.....	658
Table 3.90 Top 20 FTCMs Drugs by Sale Value in Urban Public CHCs 2016.....	659
Table 3.91 Market Shares by Major TCs: Hospitals vs. CHCs MAT Q4/2017	661
Table 3.92 Market Shares by City Tiers: Hospitals vs. CHCs MAT Q4/2017.....	661
Table 3.93 Drug Sales and Market Shares of CHCs in Six Cities 2016	661
Table 3.94 Top Five TCs in CHCs and Hospitals of Six Tier 1 & 2 Cities 2016.....	661
Table 3.95 Drugs Sales in Chinese Township Health Centers 2011-2019	662
Table 3.96 Share of THCs in Total Public Primary Healthcare Drug Consumption 2011-2019.....	662
Table 3.97 Chemical Drug Sales by TCs in Chinese Township Health Centers 2018...	663
Table 3.98 Top 20 Chemical Drug Brands by Sales Value in Chinese Township Health Centers 2018.....	663
Table 3.99 Top Drugs by Growth Rate with CNY 400M+ in 2018 Sales.....	665
Table 3.100 Fastest Growing Products in the Top 200 Drugs by Sales Value in Rep Hospitals 2018.....	665
Table 3.101 Drug Sales Value of Rep Urban Public Hospitals 18Q1-20Q1	666
Table 3.102 Sales Value of VBP Prevailing Drugs at Rep Urban Public Hospitals Q1/2018 - Q1/2020	667
Table 3.103 Sales Value of Monitored Drugs at Rep Urban Public Hospitals Q1/2018 - Q1/2020.....	668
Table 3.104 Sales Value of BMI Negotiated Drugs at Rep Urban Public Hospitals Q1/2020	668
Table 3.105 Sales of BMI Negotiated Drugs by TCs at Rep Urban Public Hospitals Q1/2018 - Q1/2020.....	669
Table 3.106 Chemical Drug Sales by TCs at Rep Urban Public Hospitals Q1/2018 - Q1/2020.....	669
Table 3.107 Drug Sales at Rep Urban Public Hospitals Q1/2018 - Q1/2020: Chemical vs. Biologics.....	670

Table 3.108 Drug Sales at Rep Urban Public Hospitals Q1/2018 - Q1/2020: Local vs. Import.....	670
Table 3.109 Drug Sales by Dosage Form at Rep Urban Public Hospitals Q1/2018 - Q1/2020.....	670
Table 3.110 Chemical Drug Sales by TCs in Chinese Urban Public Hospitals 2019	671
Table 3.111 Top 20 Chemical Drug Brands by Sales Value in Chinese Urban Public Hospitals 2019	671
Table 3.112 Chemical Drug Sales in Public Hospitals of Major Chinese Cities 2015-2019	673
Table 3.113 Vaccine Consumption at Rep Chinese Hospitals 2008-2017.....	673
Table 3.114 Chinese PPV 23 Market Shares of Producers 2017	674
Table 3.115 Chinese Hep B Vaccine Market Shares of Producers 2017	674
Table 3.116 Top 5 Human Rabies Vaccine Sales in Major Urban Hospitals 2008-2017	674
Table 3.117 Top 5 Cowpox Vaccine Sales in Major Urban Hospitals 2012-2017.....	675
Table 3.118 Top 5 Pseudomonas Aeruginosa Vaccine Sales in Major Urban Hospitals 2012-2017	675
Table 3.119 Top 5 BCG Vaccine Sales in Major Urban Public Hospitals 2012-2017...	675
Table 3.120 Top 5 Recombinant HepB Vaccine Sales in Urban Hospitals 2008-2017 .	675
Table 3.121 Sales Value of 25 Drugs under 4+7 Trial in Rep Hospital 2014-2019E	676
Table 3.122 Number of Chinese Retail Pharmacy Outlets 2006-2018	677
Table 3.123 Chinese Retail Pharmacy Drug Sales 2010-2019	678
Table 3.124 Overall Chinese Retail Pharmacy Sales 2013-2019	678
Table 3.125 Chinese Retail Pharmacy Sales: Offline vs. Online 2013-2019	679
Table 3.126 Chinese Offline Retail Pharmacy Sales by TC 2013-2019	679
Table 3.127 Chinese Offline Retail Pharmacy Sales by TC 2013-2019	679
Table 3.128 Chinese Retail Pharmacy Drug Sales 2011-2019	680
Table 3.129 Chinese Retail Pharmacy Drug Sales 2011-2019	680
Table 3.130 Chinese Offline Retail Pharmacy Drug Sales Value 2015-2019 (Urban vs. Rural)	680

Table 3.131 Chinese Offline Retail Pharmacy Drug Sales Share 2015-2019 (Urban vs. Rural).....	681
Table 3.132 Chinese Offline Retail Pharmacy Drugs Sales by City Tier 2018-2019	681
Table 3.133 Chinese Urban Offline Retail Pharmacy Drug Sales 2017-2019: Chemicals vs. TCMs	681
Table 3.134 Chinese Urban Offline Retail Pharmacy Drug Sales 2017-2019: Rx vs. OTC	681
Table 3.135 Chemical Drug Sales by TCs in Chinese Urban Offline Retail Pharmacies 2019.....	681
Table 3.136 Top 20 Drug Brands by Sales Value in Chinese Urban Offline Retail Pharmacies 2019	682
Table 3.137 Top 20 Chemical Drug Brands by Sales Value in Chinese Offline Retail Pharmacies 2019	683
Table 3.138 Top 20 Company by Sales Value in Chinese Urban Offline Retail Pharmacies 2019.....	684
Table 3.139 Growth of Top 20 OTC Drug & Health Food Players in Chinese Retail Pharmacy Market in MAT Q1/2020.....	686
Table 3.140 Top 20 Products by OTC Drug & Health Food Sales in China Retail Market in MAT Q1/2020	687
Table 3.141 Top 20 Rx Drug in China Retail Market MAT Q1/2020.....	688
Table 3.142 Growth of Top 20 OTC Drug & Health Food Players by Chinese Retail Pharmacy Sales 2019	689
Table 3.143 Top 20 OTC Drug & Health Food Products by Chinese Retail Pharmacy Sales 2019.....	690
Table 3.144 Top 20 Rx Drug Products by Chinese Retail Pharmacy Sales 2019	690
Table 3.145 Growth of Top 20 Players by Chinese Retail Pharmacy Rx Drug Sales 2019	691
Table 3.146 Retail Drug Consumption by Channel 2010-2019.....	692
Table 3.147 Segmentation of Chinese Retail Pharmacy Drug Sales 2011-2019	692
Table 3.148 # of Drug Brands with >CNY 100M Urban Retail Sales in 2018.....	693
Table 3.149 Top Drug Brands with >CNY 100M Urban Retail Sales and >100% Growth in 2018.....	693
Table 3.150 Chinese Retail Pharmacy Sales Value and Growth 2009-2018.....	694

Table 3.151 Composition of Chinese Retail Pharmacy Sales 2017-2018.....	695
Table 3.152 Share and Growth of Chinese Retail Pharmacy Sales by TCs.....	696
Table 3.153 Top 20 OTC Medicine Brands by Retail Pharmacy Sales Value 2018	696
Table 3.154 Top 20 Rx Drug Brands by Retail Pharmacy Sales Value 2018	697
Table 3.155 Market Share of Rx Drug in Chinese Retail Pharmacy Sales 2011-2018..	698
Table 3.156 Chinese Retail Pharmacy Market Segmentation in 2017.....	698
Table 3.157 Chinese Online Pharmacy Sales 2013-2019*	699
Table 3.158 Chinese Online Pharmacy Drug Sales Value 2011- 2019	699
Table 3.159 Chinese Online Drug B2C Market 2018-2023E: Rx vs. OTC (1).....	700
Table 3.160 Chinese Online Drug B2C Market 2018-2023E: Rx vs. OTC (2).....	700
Table 3.161 China Internet + Healthcare Market Size 2015-2023E	700
Table 3.162 Overview of Chinese OTC Drug Market 2018-2019.....	702
Table 3.163 Overview of Chinese OTC Drug Market 2018-2019.....	704
Table 3.164 NH’s Chinese OTC Drug Market Forecast 2018-2029.....	706
Table 3.165 Urban Retail Pharmacy Drug Sales: OTC Vs Rx 2015-2018	709
Table 3.166 Chinese OTC Drug Market Value 2016-2019.....	709
Table 3.167 Chinese OTC Drug Market Share 2016-2019.....	710
Table 3.168 Chinese OTC Drug Market Growth 2016-2019	710
Table 3.169 Market Size of Offline Retail Pharmacies 2019	710
Table 3.170 Chinese OTC Drug Market Share by TCs 2019	710
Table 3.171 Global OTC Drug Market 2015-2020.....	711
Table 3.172 Chinese OTC Drug Market by Terminal Market 2018	711
Table 3.173 Top Ten Chinese OTC Brands by Sales Value in 2019	713
Table 3.174 Chinese Drug Market Size by Major Segments 2014-2017.....	720
Table 3.175 Chemical Drug Sales in Public Hospitals by Major Cities 2019	721
Table 3.176 Chemical Drug Sales in Beijing Public Hospitals 2015-2019	721
Table 3.177 Top 10 Chemical Drug Brands in Beijing Public Hospitals 2019	722
Table 3.178 Chemical Drug Sales in Guangzhou Public Hospitals 2015-2019	722

Table 3.179 Top 10 Chemical Drug Brands in Guangzhou Public Hospitals 2019	722
Table 3.180 Chemical Drug Sales in Shanghai Public Hospitals 2015-2019	723
Table 3.181 Top 10 Chemical Drug Brands in Shanghai Public Hospitals 2019.....	723
Table 3.182 Chemical Drugs Sales in Rep Public Hospitals in 16 Major Cities 2018 ..	723
Table 3.183 GDP and Population in Beijing, Shanghai & Guangzhou 2018.....	724
Table 3.184 Top 5 TCs by Public Hospital Sales in Beijing, Shanghai and Guangzhou 2018	724
Table 3.185 Top 10 Chemical Drug Brands by Sales in Beijing Public Hospitals 2018	725
Table 3.186 Top 10 Chemical Drug Brands by Sales in Shanghai Public Hospitals 2018	725
Table 3.187 Top 10 Chemical Drug Brands by Sales in Guangzhou Public Hospitals 2018	725
Table 3.188 Shanghai Drug Market by Terminal Sales Channels 2019.....	726
Table 3.189 Quarterly Shanghai Hospital Drug Market* 2015-2019	726
Table 3.190 Shanghai Hospital Drug Market by TCs 2018-2019	727
Table 3.191 Shanghai Drug Market – Tier 1 Therapeutic Category Growth.....	727
Table 3.192 Top 10 Drug Suppliers to Shanghai Hospitals 2019	727
Table 3.193 Top 10 Drug Products by Sales in Shanghai Hospitals 2019.....	728
Table 3.194 Provincial Level Hospital Drug Markets 2017.....	728
Table 3.195 Chinese Hospitals Market Growth by City Tiers 2017	729
Table 3.196 Chinese Hospitals Market Share by City Tiers Q4/2017	729
Table 3.197 Drug Sales Champions in Rep Public Hospitals of 22 Cities/Regions 2016	729
Table 3.198 Regional Chinese Pharma Distribution Sales in 2017.....	730
Table 3.199 Regional Pharmaceutical Distributor Sales Structure 2016-2017.....	731
Table 3.200 Top 15 Regional Drug Distributors by Operating Revenues 2016.....	732
Table 3.201 Geographic Coverage of 15 Regional Drug Distributors.....	733
Table 3.202 Top 15 Regional Drug Distributors by Gross Profit Margin 2016.....	733
Table 3.203 Share and Growth of Major Chinese Provincial Retail Pharmacy Markets 2018.....	734

Table 3.204 Offline Retail Pharmacy Drug Sales by City Tiers 2017-2018.....	735
Table 3.205 Top 10 Chemical Drug TCs by Urban Retail Pharmacy Sales in North China 2016.....	735
Table 3.206 Top 10 TCM TCs by Urban Retail Pharmacy Sales in North China 2016	736
Table 3.207 Top 10 Chemical Drug TCs by Urban Retail Pharmacy Sales in East China 2016.....	736
Table 3.208 Top 10 TCM TCs by Urban Retail Pharmacy Sales in East China 2016...	737
Table 3.209 Top 10 Chemical Drug TCs by Urban Retail Pharmacy Sales in West China 2016.....	737
Table 3.210 Top 10 TCM TCs by Urban Retail Pharmacy Sales in West China 2016..	737
Table 3.211 Top 10 Chemical Drug TCs by Urban Retail Pharmacy Sales in Central South China	738
Table 3.212 Top 10 TCM TCs by Urban Retail Pharmacy Sales in Central South China 2016.....	738
Table 3.213 Top 15 Provinces by Share of CHC Patient Visits 2015	739
Table 3.214 Growth of Drugs Sales Value in Tier 1 Cities 2015: Hospitals VS. CHCs	739
Table 3.215 Regional Shares of Chinese BMI Spending 2018.....	740
Table 3.216 Average # of Months BMI Surplus May Last by Region 2018.....	740
Table 3.217 Top Ten Pharma Cos by Chinese Hospital and Retail Drug Sales 2018....	743
Table 3.218 Hospital Market Shares of Local, JV and Imported Drugs 2006-2019.....	743
Table 3.219 Urban Hospital Drug Sales Structure: MNCs vs. Domestic 2013-2019 ..	744
Table 3.220 Hospital Drug Sales Growth by City Tier: MNCs vs. Domestic, 2016-2019	744
Table 3.221 MNC Chinese Urban Hospital Drug Market Shares by City Tiers 2013-2019	744
Table 3.222 Healthcare Expenditure Comparisons in Ten Countries 2005-2018*	745
Table 3.223 China Revenues of MNCs in 2019	745
Table 3.224 CAGR of Top 11 MNCs Sales in Rep Chinese Hospitals 2013-2018	745
Table 3.225 Segmentation of 2019 MNC Drug Sales in China by Product Launch Time (1)	746

Table 3.226 Segmentation of 2019 MNC Drug Sales in China by Product Launch Time (2)	746
Table 3.227 China Sales Segmentation of Top 11 MNCs 2019	747
Table 3.228 Chinese Rep Hospital Market Share by Tier 2018: MNCs vs. Domestics	747
Table 3.229 Roche’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	747
Table 3.230 AZ’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	747
Table 3.231 Novartis’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	748
Table 3.232 Sanofi’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	748
Table 3.233 Eli Lilly’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	748
Table 3.234 Bayer’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	748
Table 3.235 GSK’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	749
Table 3.236 Pfizer’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	749
Table 3.237 BMS’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	749
Table 3.238 MSD’s Chinese Rep Hospital Drug Sales Segmentation by TCs 2018	749
Table 3.239 Ranking of Top 19 Pharma Cos by Sales Value in Chinese Rep Hospitals 2010-2018	750
Table 3.240 Drug Sales/Growth in Chinese Rep Hospitals 2016-2018: MNCs vs. Domestics	750
Table 3.241 Drug Sales/Growth in Chinese Rep Hospitals 2016-2018: Top 10 Players	751
Table 3.242 China Sales Growth of Top 10 Pharma Cos 2010-2020E: MNCs vs. Domestics	751
Table 3.243 # of New Drug Approvals 2016-2019: MNCs vs. Domestics	751
Table 3.244 # of New Drug Approvals of Leading Players in 2019	751
Table 3.245 Overview of National Reimbursement Drug List (NRDL) 2000-2019	752
Table 3.246 # of New/Renewed 2019 NRDL Product Listings of Leading Players	752
Table 3.247 Share of Chinese Clinical Trial Approvals by Company Type 2016-2019	753
Table 3.248 Share of Chinese Clinical Trial Approvals by TCs 2019: China vs. U.S.	753
Table 3.249 Top 7 Diseases by Mortality Rate among Chinese Urban Residents	756
Table 3.250 Chinese Oncology Drug Market Project 2008-2018	758

Table 3.251 Share of Anticancers & Immuno-Regulators in Chinese Rx Drug Market 2016-2018	759
Table 3.252 The Latest Approval and Development of PD-1/PD-L1 Antibodies in China	765
Table 3.253 The Comparison among Approved PD-1 Antibodies for Hodgkin’s lymphoma in China.....	765
Table 3.254 The Comparison among Approved PD-1 Antibodies for Melanoma in China	766
Table 3.255 The Current Development Pipeline for PD-1 Antibodies of Leading Chinese Pharma Companies	766
Table 3.256 Major Chinese Pharmas Developing DPP-4 Inhibitors	778
Table 3.257 Major Chinese Pharmas Developing GLP-1 Agonists.....	779
Table 3.258 Major Chinese Pharmas Developing Insulin	779
Table 3.259 Major Chinese Pharmas Developing SGLT-2 Inhibitors	780
Table 3.260 Consumption of Chemical Diabetes Drugs of Major Provincial level Public Hospitals 2013-2018	781
Table 3.261 Top Ten Diabetes Drugs in Major Provincial level Public Hospitals 2018	781
Table 3.262 Shares of Top Ten Diabetes Drug Suppliers to Major Provincial level Public Hospitals 2018	781
Table 3.263 Diabetes Chemical Drug by Sales in Major Urban Public Hospitals 3Qs/2018	782
Table 3.264 Diabetes Chemical Drug by Category in Urban Public Hospitals 3Qs/2018	783
Table 3.265 Diabetes Chemical Drugs by Dosage Form in Urban Public Hospitals 3Qs/2018.....	783
Table 3.266 Top Ten Diabetes Drugs by Sales in Urban Public Hospitals 2016-3Qs/2018	783
Table 3.267 Top Ten Diabetes Drug Brands by Sales in Urban Public Hospitals 2016-3Qs/2018.....	784
Table 3.268 Share of Digestive Tract & Metabolic Drugs in Chinese Rx Drug Market 2016-2018	784
Table 3.269 Chinese Rx Drug Market Share: Cardiovascular Drugs 2015-2017.....	785

Table 3.270 Cardio-/Cerebro-vascular Drug Consumption in Public Hospitals of 16 Major Cities 2007-2016	785
Table 3.271 Top 10 Cardio- and Cerebro-vascular Drugs in Public Hospitals of 16 Major Cities 2016.....	786
Table 3.272 Leading TCs of Cardiovascular Drug Consumption by Rep Urban Hospitals 2018.....	786
Table 3.273 Top 10 Suppliers of Cardiovasculars to Rep Urban Hospitals 2018	786
Table 3.274 Top 10 Cardiovascular Drugs by Value of Rep Urban Hospitals 2018	787
Table 3.275 Cause of Respiratory Diseases in Shanghai H1/2016	790
Table 3.276 COPD Incidence Rate by Gender in Shanghai.....	791
Table 3.277 COPD Incidence Rate by Age in Shanghai	791
Table 3.278 Top 10 COPD Drugs in Shanghai Rep Hospitals.....	791
Table 3.279 Approval and Reimbursement of Drugs for Listed Rare Diseases (Batch 1) in China	797
Table 3.280 22 Rare Diseases Treated Off-label by Existing Drugs on the Market	797
Table 3.281 Treatment Costs of Unreimbursed Drugs for 13 Rare Diseases.....	798
Table 3.282 Statistical Summary of Chinese Senior Population.....	800
Table 3.283 Consumption of Geriatric Drugs in Major Urban Public Hospitals 2011-2014	800
Table 3.284 PD Drug Consumption by Rep Chinese Hospitals 2013-2017	805
Table 3.285 Top 10 PD Drugs in Chinese Rep Hospitals by Share in 2017	805
Table 3.286 Lung Cancer TKIs in the Chinese market	812
Table 3.287 Generic and Innovative TKIs under Development in China	814
Table 3.288 Leading Causes of Death in China	820
Table 3.289 Growth of NCDs in China 2002-2012	820
Table 3.290 NCD Awareness, Treatment and Control Rates: China v.s. USA.....	821
Table 3.291 # of Newly-included Drug Products by TCs in 2017 NRDL	821
Table 3.292 Chinese Clinical Trials by Disease Categories.....	821
Table 3.293 China's Population Structure by Age Group 1995-2040E	822

Table 3.294 Rear and Forward View of Chinese Drug Markets for Three Major Chronic Diseases.....	822
Table 3.295 Chinese Drug Markets for Three Major Chronic Diseases 2016-2018 (1)	823
Table 3.296 Chinese Drug Markets for Three Major Chronic Diseases 2016-2018 (2)	823
Table 3.297 Top 10 Provinces by Sales Share of Three Chronic Disease Drugs in China 2018.....	823
Table 3.298 Chinese Drug Markets for Three Major Chronic Diseases by City Tier and Terminal Markets	824
Table 3.299 Chinese Drug Markets for Three Major Chronic Diseases 2016-2018: MNCs vs. Domestics (1)	824
Table 3.300 Chinese Drug Markets for Three Major Chronic Diseases 2016-2018: MNCs vs. Domestics (2)	824
Table 3.301 Chinese Drug Markets for Three Major Chronic Diseases 2016-2018: MNCs vs. Domestics (3)	825
Table 3.302 Rear/Forward View of Chinese Antihypertensive Drug Market 2016-2023E (1).....	825
Table 3.303 Rear/Forward View of Chinese Antihypertensive Drug Market 2016-2023E (2).....	825
Table 3.304 Forecast of Chinese Antihypertensive Drug Market by Terminals 2018-2023E	826
Table 3.305 Segmentation of the Chinese Antihypertensive Drug Market 2016-2018 (1)	826
Table 3.306 Segmentation of the Chinese Antihypertensive Drug Market 2016-2018 (2)	826
Table 3.307 Average Price of Antihypertensive Drugs by Terminal Markets 2016-2018	826
Table 3.308 Sale Volume of Antihypertensive Drugs by Terminal Markets 2016-2018	826
Table 3.309 Market Share by Volume of Antihypertensive Drugs by Channels 2016-2018	827
Table 3.310 Top 10 Antihypertensive Drugs in Urban Hospitals 2018	827
Table 3.311 Top 10 Antihypertensive Drugs in County Hospitals 2018.....	827
Table 3.312 Top 10 Antihypertensive Drugs in CHCs 2018.....	828

Table 3.313 Rear/Forward View of Chinese Oral Hypoglycemic Drug Market 2016-2023E (1)	828
Table 3.314 Rear/Forward View of Chinese Oral Hypoglycemic Drug Market 2016-2023E (2)	828
Table 3.315 Forecast of Chinese Oral Hypoglycemic Drug Market by Terminals 2018-2023E	829
Table 3.316 Segmentation of the Chinese Hypoglycemic Drug Market 2016-2018 (1)	829
Table 3.317 Segmentation of the Chinese Hypoglycemic Drug Market 2016-2018 (2)	829
Table 3.318 Average Price of Oral Hypoglycemic Drugs by Terminal Markets 2016-2018	829
Table 3.319 Sale Volume of Oral Hypoglycemic Drugs by Terminal Markets 2016-2018	829
Table 3.320 Market Share by Volume of Oral Hypoglycemic Drugs by Terminal Markets 2016-2018.....	830
Table 3.321 Top 10 Oral Hypoglycemic Drugs in Urban Hospitals 2018	830
Table 3.322 Top 10 Oral Hypoglycemic Drugs in County Hospitals 2018	830
Table 3.323 Top 10 Oral Hypoglycemic Drugs in CHCs 2018.....	831
Table 3.324 Rear/Forward View of Chinese Lipid-lowering Drug Market 2016-2023E (1)	831
Table 3.325 Rear/Forward View of Chinese Lipid-lowering Drug Market 2016-2023E (2)	831
Table 3.326 Forecast of Chinese Lipid-lowering Drug Market by Terminals 2018-2023E	832
Table 3.327 Segmentation of the Chinese Lipid-lowering Drug Market 2016-2018 (1)	832
Table 3.328 Segmentation of the Chinese Lipid-lowering Drug Market 2016-2018 (2)	832
Table 3.329 Average Price of Lipid-lowering Drugs by Terminal Markets 2016-2018.	832
Table 3.330 Sale Volume of Lipid-lowering Drugs by Terminal Markets 2016-2018...	833
Table 3.331 Market Share by Volume of Lipid-lowering Drugs by Terminal Markets 2016-2018.....	833
Table 3.332 Top 10 Lipid-lowering Drugs in Urban Hospitals 2018.....	833

Table 3.333 Top 10 Lipid-lowering Drugs in County Hospitals 2018.....	833
Table 3.334 Top 10 Lipid-lowering Drugs in CHCs 2018.....	834
Table 3.335 Chinese Generic Drug Market Size 2016-2021E.....	840
Table 3.336 Generic Drug Shares in Three Major Terminal Drug Markets 2016	840
Table 3.337 Top 10 Generic Drug TCs in Chinese Rep Hospitals 2016.....	840
Table 3.338 Top 13 Generic Drug Cos with CNY 10B+ Revenue 2016	841
Table 3.339 Major Product Market Shares: Originator Drugs vs. Generics 2017	841
Table 3.340 Oral WM Market Shares: Originators vs. Generics/MNCs vs. Domestics 2017	842
Table 3.341 Chinese Western Medicine Market Shares MAT Q3/2018	842
Table 3.342 Top 10 Brands by Value in China vs. the U.S. MAT Q3/2018.....	842
Table 3.343 Chinese Pharma Market Growth Shifting Towards Therapeutics 11/2018 YTD	842
Table 3.344 Chinese Public Medical Institution Drug Sales 2015-2019: Chemicals vs. FTCMs	843
Table 3.345 Chinese Public Medical Institution Drug Sales 2019: Chemicals vs. FTCMs	843
Table 3.346 Chemical Drugs Sales Value in Rep Public Hospitals of Major Cities 2013-2018.....	844
Table 3.347 Chemical Drugs Sales Value by TCs in Rep Public Hospitals of Major Cities 2018.....	844
Table 3.348 Top 20 Chemical Drugs by Sales Value in Rep Public Hospitals of Major Cities 2018	845
Table 3.349 Top 20 Chemical Drug Brands by Sales Value in Rep Hospitals of Major Cities 2018	846
Table 3.350 Paclitaxel Market Shares in Rep Public Hospitals of Major Cities 2018 ..	847
Table 3.351 13 Chemical Drugs with CNY 1B+ Sales in Urban Chinese Retail Pharmacies 2018.....	847
Table 4.1 Number of Pharma Manufacturers 2013-2019	865
Table 4.2 Number of Pharma Distribution License Holders 2013-2019	866
Table 4.3 Number of Retail Pharmacy Chain Companies 2011-2018.....	866

Table 4.4 Number of Retail Pharmacy Stores 2011-2019	866
Table 4.5 Biologics Approved for the First Time in China H1/2020	868
Table 4.6 New Indication Approvals of Small Molecule Drugs H1/2020	868
Table 4.7 Urgently-Needed Foreign New Drugs First Approved in China H1/2020.....	868
Table 4.8 # of Drug Registration Applications Accepted by CDE 2011-2019.....	869
Table 4.9 Breakdown of Registration Applications under CDE Review 2018-2019.....	869
Table 4.10 Breakdown of Chemical Drug Registration Applications under CDE Review 2019 (1)	869
Table 4.11 Breakdown of Chemical Drug Registration Applications under CDE Review 2019 (2)	870
Table 4.12 # of CDE Review-concluded Applications 2019	870
Table 4.13 Breakdown of CDE Review-concluded Chemical Drug Applications 2019	870
Table 4.14 Breakdown of CDE Recommendations for Chemical Drug Applications 2019	870
Table 4.15 CDE-Accepted Applications in 2016-2019	871
Table 4.16 Breakdown of CDE-Accepted Applications 2016-2019	871
Table 4.17 Breakdown of CDE-Accepted Applications Needing Review 2016-2019 ..	871
Table 4.18 CDE-accepted Chemical Drug Registration Applications in 2011-2019.....	872
Table 4.19 Breakdown of CDE-accepted Chemical New Drug INDs by TCs 2019.....	872
Table 4.20 Breakdown of CDE-accepted Chemical New Drug NDAs by TCs 2019	873
Table 4.21 Breakdown of TCM Registration Applications Accepted by the CDE in 2012-2019.....	873
Table 4.22 Breakdown of Biologics Registration Applications Accepted by the CDE in 2012-2019.....	874
Table 4.23 Breakdown of Drug Applications Concluding CDE Review 2013-2019.....	874
Table 4.24 # of CDE Concluded Chemical Drug Registration Applications in 2012-2019	875
Table 4.25 Breakdown of CDE Recommendations for Chemical Drug Applications in 2019.....	875
Table 4.26 Breakdown of Chemical Drug Registration NDA and IND Applications 2015-2019.....	876

Table 4.27 Breakdown of CDE Approved Class 1 Chemical New Drug INDs by TCs 2019	876
Table 4.28 Breakdown of CDE Recommendations for TCM Registration Applications in 2019.....	876
Table 4.29 # of Concluded TCM Registration Applications by the CDE in 2012-2019	877
Table 4.30 Breakdown of TCM Registration NDA and IND Applications 2015-2019.	877
Table 4.31 Breakdown of CDE Approved TCM INDs by TCs 2019	877
Table 4.32 Breakdown of CDE Recommendations for Biologics Applications in 2019	878
Table 4.33 # of Concluded Biological Product Registration Applications 2012-2019..	878
Table 4.34 Breakdown of Biologics Registration NDA and IND Applications 2015-2019	878
Table 4.35 Breakdown of CDE Approved Biologic INDs by TCs 2019	878
Table 4.36 Breakdown of CDE Approved Biologic NDAs by TCs 2019.....	879
Table 4.37 # of Priority Review Products Applications 2016-2019	879
Table 4.38 # of Priority Review Products Approvals 2016-2019	880
Table 4.39 Breakdown of Communication Meeting Requests and Fulfillment with CDE 2019.....	880
Table 4.40 Structure of Drug Applications Accepted by CDE for Priority Review	881
Table 4.41 Annual # of Drug Applications Accepted by CDE for Priority Review	882
Table 4.42 Snapshot of grounds on which priority review are granted 2016-11/2018 ..	882
Table 4.43 Drug Applications under Accelerated Review by the CDE 2004-2017.....	883
Table 4.44 Composition of Drug Applications under Accelerated Review by the CDE 2004-2017	883
Table 4.45 Pharma-related Regulatory Introductions in China in 2015 - H1/2020.....	887
Table 4.46 Pharma-related Regulations and Policies Newly Issued in H1/2020.....	887
Table 4.47 Quarterly Pharma-Related Regulatory Introductions in China in 2014 - 2019	888
Table 4.48 Pharma-related Regulations and Policies Newly Issued in 2019.....	889
Table 4.49 # of Generic Drug Applications Accepted by CDE 2015-2018.....	910
Table 4.50 Share of Generic Drug Application by Class Type 2015-2018.....	910

Table 4.51 Top 15 Companies by Generic Drug Applications 2018.....	910
Table 4.52 Top 15 Companies by Generic Drug Applications 2017.....	911
Table 4.53 The Internal Organizational Structure and Departmental Responsibilities of Provincial Branches of NHSA	953
Table 4.54 The Internal Organizational Structure and Departmental Responsibilities of Local HSA Branches below Provincial Level.....	954
Table 4.55 New Classification System for Registration and Exclusivity of Chemical Drugs	977
Table 4.56 Overview of Drug Application Submissions from MAH Trial Areas*	1045
Table 5.1 Overall Chinese Terminal Drug Market Growth and Value 2010-H1/2019.	1420
Table 5.2 Chinese Drug Market Segmentation 2019: Terminals and Sub-markets	1421
Table 5.3 China’s Three Major Terminal Drug Markets 2010-2019 – Retail Value and Market Share	1421
Table 5.4 Size of Chinese Pharmaceutical Market 2013-2019	1422
Table 5.5 Innovative Drug Sales Value in China 2012-2018	1422
Table 5.6 Overall Chinese Pharma Market by Terminal Market 2018	1423
Table 5.7 Overall Chinese Pharma Market by Sales Channel 2018.....	1424
Table 5.8 Overall Chinese Pharma Market 2018: Rx Drugs vs. OTC Drugs	1424
Table 5.9 Chinese Rx Drug Market by Terminal Market 2018.....	1424
Table 5.10 Chinese OTC Drug Market by Terminal 2018	1424
Table 5.11 China Drug Market Size and Growth 2007-2020E	1425
Table 5.12 Chinese Drug Market Share by Sales Channels 2007-2020E	1425
Table 5.13 Chinese Retail Pharmacy Quarterly Sales and Growth 2007-Q1/2020	1426
Table 5.14 Chinese Hospital Drug Market 2011- Q1/2020.....	1427
Table 5.15 Chinese Public Medical Institution Drug Sales 2015-2019	1429
Table 5.16 Public Medical Institution Drug Consumption by Facility Type 2010-2019	1429
Table 5.17 Chinese Urban Rep Hospital Drug Market 2012-2019	1430
Table 5.18 Chinese Retail Pharmacy Drug Market Overview 2011-2019.....	1432
Table 5.19 Size of Chinese Retail Pharmacy Market 2011-2018.....	1433

Table 5.20 # of Retail Pharmacy Stores and Their Service Population 2010-2018.....	1433
Table 5.21 Chinese Pharma Industry Performance M1-7/2019.....	1437
Table 5.22 Chinese Pharma Industry Performance 2005-2019.....	1437
Table 5.23 Global and China Performances of Selected MNCs in H1/2020.....	1444
Table 5.24 Iressa Quarterly Sales in China Q1/2019-Q2/2020.....	1444
Table 5.25 Lipitor and Novasc Quarter Sales in China Q1/2019-Q2/2020	1445
Table 5.26 Snapshot of MNCs Pharma Revenues in China 2019.....	1445
Table 5.27 Top Eight MNCs by China Revenue Size 2019.....	1446
Table 5.28 Top Six Drug Products by Revenue in Urban Chinese Hospitals 2019.....	1446
Table 5.29 Import New Drugs Launched by MNCs in China 2019	1452
Table 5.30 Top Ten A Share-Listed Chinese Pharma Cos by Revenue in Q1/2020 ...	1456
Table 5.31 Top Ten A Share-Listed Chinese Pharma Cos by Net Profit in Q1/2020 ..	1457
Table 5.32 Pre-profit Chinese Biotech Startups Listed at HKSE as of Dec 9, 2019 ...	1457
Table 5.33 R&D Spending/P&L of HKSE-listed Pre-profit Chinese Biotechs.....	1458
Table 5.34 Performance of HKSE-listed Pre-profit Chinese Biotechs	1458
Table 5.35 Performance of 15 Chinese Biotech Companies Listed on HKSE 2019 ...	1459
Table 5.36 Top 31 Listed Chinese Pharma Companies by R&D Spending 2019.....	1460
Table 5.37 Summary of Chinese Pharma Events Q2/2020 and H1/2020	1515
Table 5.38 Summary of Sino-foreign Licensing Deals in H1/2020 (1).....	1516
Table 5.39 Summary of Sino-foreign Licensing Deals in H1/2020 (2).....	1517
Table 5.40 Summary of Sino-foreign Licensing Deals in H1/2020 (3).....	1518
Table 5.41 Summary of Sino-foreign Licensing Deals in H1/2020 (4).....	1519
Table 5.42 Summary of Sino-foreign Contract Research/Collaborative R&D Agreements in H1/2020 (1).....	1520
Table 5.43 Summary of Sino-foreign Contract Research/Collaborative R&D Agreements in H1/2020 (2).....	1521
Table 5.44 Summary of Selected JV/Strategic Alliance Deals in H1/2020 (1)	1522
Table 5.45 Summary of Selected JV/Strategic Alliance Deals in H1/2020 (2)	1523
Table 5.46 Summary of Sino-foreign M&A Deals in H1/2020	1524

Table 5.47 Number of Recorded New Drug Projects in China in 2015 - H1/2020	1524
Table 5.48 Chinese New Drug Projects by R&D Phase in 2012-2019 and H1/2020 ..	1524
Table 5.49 Summary of Chinese New Drug Projects Recorded in H1/2020 (1)	1525
Table 5.50 Summary of Chinese New Drug Projects Recorded in H1/2020 (2)	1527
Table 5.51 Pharma-related Regulatory Introductions in China in 2015 - H1/2020	1527
Table 5.52 Pharma-related Regulations and Policies Newly Issued in H1/2020	1528
Table 5.53 Summary of Chinese Pharma Events in 2014 – 2019	1529
Table 5.54 Summary of Sino-foreign Licensing Deals in 2019 (1)	1529
Table 5.55 Summary of Sino-foreign Licensing Deals in 2019 (2)	1530
Table 5.56 Summary of Sino-foreign Licensing Deals in 2019 (3)	1531
Table 5.57 Summary of Sino-foreign Licensing Deals in 2019 (4)	1532
Table 5.58 Summary of Sino-foreign Licensing Deals in 2019 (5)	1533
Table 5.59 Summary of Sino-foreign Licensing Deals in 2019 (6)	1534
Table 5.60 Summary of Sino-foreign Contract Research/Collaborative R&D Agreements in 2019 (1)	1535
Table 5.61 Summary of Sino-foreign Contract Research/Collaborative R&D Agreements in 2019 (2)	1536
Table 5.62 Summary of Selected JV/Strategic Alliance Deals in 2019 (1).....	1537
Table 5.63 Summary of Selected JV/Strategic Alliance Deals in 2019 (2).....	1538
Table 5.64 Summary of Selected JV/Strategic Alliance Deals in 2019 (3).....	1539
Table 5.65 Summary of Sino-foreign M&A Deals in 2019	1540
Table 5.66 Leading Chinese Biotech Fund-raising Deals in H1/2019	1541
Table 5.67 Projected Chinese Pharma Market Growth (CAGR 2018-2023).....	1550
Table 5.68 Total Chinese Pharma Market Sales Projections (2018-2023) CNY (mln)	1551
Table 5.69 Total Chinese Pharma Market Sales Projections (2018-2023) US\$ (mln).	1551
Table 6.1 Class I New Drugs Approved by Type in China as of 2018.....	1664
Table 6.2 Class I New Drugs Approved in China by TCs as of 2018	1665
Table 6.3 20 Class I New Drugs Approved in China as of 2018.....	1665
Table 6.4 # of Class 1 New Drugs Accepted by CDE 2016-2017	1667

Table 6.5 CDE-Accepted Class 1 New Drug Applications by TCs 2017	1667
Table 6.6 CDE-Accepted Class 1 Anticancer Applications by Mechanism 2017	1667
Table 6.7 Applicant Ranking by # of Class 1 CDE-Accepted New Drug Applications 2017	1668
Table 6.8 Class 1 New Drugs Approvals in 2003-2015	1668
Table 6.9 Class 1 New Drug Applicants by Ownership 2003-2015	1669
Table 6.10 Class 1 New Drug Applicants by Company Size 2003-2015	1669
Table 6.11 Class 1 New Drug Applicants by Stock Listing 2003-2015	1669
Table 6.12 Class 1 New Drug Approvals by # of Producers 2003-2015	1669
Table 6.13 Approved Class 1 New Drugs by Indications 2003-2015	1670
Table 6.14 Number of Recorded New Drug Projects in China in 2015 - H1/2020	1670
Table 6.15 Chinese New Drug Projects by R&D Phase in 2012-2019 and H1/2020 ..	1671
Table 6.16 Summary of Chinese New Drug Projects Recorded in H1/2020 (1)	1671
Table 6.17 Summary of Chinese New Drug Projects Recorded in H1/2020 (2)	1672
Table 6.18 Summary of Chinese New Drug Projects Recorded in H1/2020 (3)	1673
Table 6.19 No. of Recorded Novel New Drug Projects in China in 2014 – 2019	1673
Table 6.20 Chinese New Drug Projects by R&D Phase in 2010 – 2019	1674
Table 6.21 Summary of Chinese New Drug Projects Recorded in 2019 (1)	1674
Table 6.22 Summary of Chinese New Drug Projects Recorded in 2019 (2)	1675
Table 6.23 Summary of Chinese New Drug Projects Recorded in 2019 (3)	1676
Table 6.24 Foreign New Drugs in Urgent Clinical Need – Approved and To-Be-Approved in China	1677
Table 6.25 Foreign New Drugs in Urgent Clinical Need Yet to Seek Registration in China	1677
Table 6.26 # of Innovative Drugs Approved in China	1691
Table 6.27 Launch Lag between China and Global First Launch	1691
Table 6.28 # of NRDL Listed Molecules (2004–2019)	1691
Table 6.29 Magnitude of Price Reduction (%)	1692
Table 6.30 Breakdown of NRDL-negotiation Drugs by TA, Western Drugs Only	1692

Table 6.31 2015-2019E Revenue Growth for VBP* Impacted LOE Originators.....	1692
Table 6.32 A Brief History of MNCs Commercial Performance in China	1692
Table 6.33 The Latest Approval & Development Of PD-1/PD-L1 Antibodies in China	1700
Table 6.34 The Comparison Among Approved PD-1 Antibodies for Hodgkin’s Lymphoma in China	1701
Table 6.35 The Comparison among Approved PD-1 Antibodies for Melanoma in China	1701
Table 6.36 The Current Development Pipeline for PD-1 Antibodies of Leading Chinese Pharma Companies.....	1701
Table 6.37 Biosimilar Development Activity in East Asia.....	1734
Table 6.38 16 Heavy-weight New Drugs Expected to be Approved in China 2020....	1735
Table 6.39 Chinese CROs/CMDOs Listed in Mainland China, HK and Taiwan	1750
Table 6.40 Performance of 41 A-Share Listed Chinese CRO Companies 2018	1752
Table 6.41 Overall Performance of 41 A-Share Listed Chinese CRO Cos 2015-2018	1753
Table 6.42 Chinese Pharmaceutical CRO Market Size 2011-2021E	1756
Table 6.43 Four CRO Companies in Shanghai Stock Market 2016-2017	1756
Table 6.44 No. of Drug Clinical Trials Registered on the CDE Platform 2013-2017 .	1761
Table 6.45 Top 10 Products by # of Registered Drug Clinical Trials 2017	1761
Table 7.1 Major Pharma Marketing Spending by Channels in China 2016.....	1849
Table 7.2 Spending Shares of Chinese Pharma Sales & Promotion Channels 2017 ...	1919
Table 7.3 Top 10 Pharma Cos in China by Sales & Promotional Spending 2017	1919
Table 7.4 Top 10 Drug Brands in China by Sales & Promotional Spending 2017	1920
Table 7.5 Top 10 Pharma Companies in China by Number of FTE (MRs) 2017	1921
Table 7.6 Spending Trends on Chinese Pharma Sales & Promotion Channels 2017...	1921
Table 7.7 Online Learning Time of Chinese Physicians at Different Rankings.....	1922
Table 9.1 Top 42 Chinese Pharma Billionaires in Hurun Global Rich List 2019	2295

LIST OF CHARTS

Chart 1.1 Core Business Revenues of Broad Chinese Pharma Industry 2006 – 2019E	143
Chart 1.2 Pretax Net Profitability Trend of the Chinese Pharma Industry 2000-2019..	143
Chart 1.3 Revenues of Chinese Biologic Product Subsector 2006-2017.....	166
Chart 1.4 Net Profit of Chinese Biologic Products Subsector 2006-2017.....	167
Chart 1.5 Profit Margins of the Chinese Pharma Distribution Sector Since 2002	191
Chart 1.6 R&D Centers of RDPAC Members by Research Stage in China	204
Chart 1.7 R&D Centers of RDPAC Members by Function in China	205
Chart 1.8 Locations of R&D Centers of RDPAC Members in China.....	205
Chart 1.9 Chinese Market Access by New Drugs – 1 Year After Launch	206
Chart 1.10 Chinese Market Access by New Drugs – 2 Years after Launch.....	207
Chart 1.11 Number of Chinese Retail Pharmacy Stores 2006-2018.....	299
Chart 1.12 Number of Chinese Retail Pharmacy Chains 2006-2018	300
Chart 1.13 Number of Outlets Owned by Chinese Retail Pharmacy Chains 2006-2018	300
Chart 1.14 Number of Independent Chinese Retail Pharmacy Stores 2006-2018.....	301
Chart 1.15 Structure of Retail Pharmacy Outlets 2006-2018	301
Chart 1.16 Chinese Sales of SIP Pediatric Vaccines 2006-2016.....	321
Chart 1.17 Chinese Sales of Adult Vaccines 2006-2016.....	321
Chart 2.1 Per capital Healthcare Expenditures 2016 (\$): China vs. Other Countries....	358
Chart 2.2 Medical Institutions Inpatient Beds in China 2009-2019	370
Chart 2.3 Number of Medical Institutions in China 2009-2019	370
Chart 2.4 Healthcare Professionals in China 2009-2019	372
Chart 2.5 Outpatient Visits in China 2009-2019.....	374
Chart 2.6 Inpatients of Medical Institutions in China 2009-2019	374
Chart 2.8 Healthcare Spending by Funding Source 1980-2019 (%)	444
Chart 3.1 Growth of Healthcare Expenditures in China Since 2000	567
Chart 3.2 Growth of Per Capita Healthcare Expenditures in China Since 1990	567

Chart 3.3 Market Share Trend of County Level Hospitals in China 2014-2020.....	654
Chart 3.4 Hospital Sales of Gastric Cancer Drugs in Key Chinese Citeis.....	769
Chart 3.5 Hospital Shares of Gastric Cancer Drugs in Key Chinese Citeis.....	769
Chart 3.6 Hospital Sales of Fluorouacil Series in Key Chinese Cities	771
Chart 3.7 Hospital Sales of Tegafur in Key Chinese Cities	771
Chart 3.8 Hospital Sales of Capecitabine in Key Chinese Cities.....	772
Chart 3.9 Hospital Sales of Apatinib in Key Chinese Cities.....	774
Chart 4.1 Administrative Structure of Drug Regulation in China.....	940
Chart 4.2 Application and Approval Procedures for Clinical Trials	981
Chart 4.3 Application and Approval Procedure for Imported Drugs (1).....	1015
Chart 4.4 Application and Approval Procedure for Imported Drugs (2).....	1015
Chart 4.5 Supplemental Application and Approval Procedure for Imported Drugs (1)	1016
Chart 4.6 Supplemental Application and Approval Procedure for Imported Drugs (2)	1016
Chart 4.7 Compulsory License Application Process.....	1254
Chart 4.8 The Model for Realizing Minimum Drug Resale Profit Margin in China...	1338
Chart 7.1 Structure of the Chinese Pharmaceutical Distribution System in the Old Days	1819
Chart 7.2 Approval Process of Hospital Drug Purchase	1854
Chart 7.3 Hospital Market Potential Assessment Process.....	1858
Chart 7.4 Pharmaceutical Distribution Channels in the Urban Areas	1878
Chart 7.5 Pharmaceutical Distribution through Retail Pharmacies.....	1879
Chart 7.6 Pharmaceutical Distribution in Sub-urban and Rural Areas (3rd Terminal Market)	1880
Chart 7.7 Dominant Distribution Models Used by MNCs in China	1886

TABLE OF ABBREVIATIONS

ADR – Adverse Drug Reaction	GDP – Gross Domestic Products
AmCham – American Chamber of Commerce	GLP – Good Laboratory Practices
API – Active Pharmaceutical Ingredients	GMP – Good Manufacturing Practices
APP – Administrative Protection of Pharmaceuticals	GSP – Good Supply Practices
ANDA – Abbreviated New Drug Application	IFPMA – International Federation of Pharmaceutical Manufacturer Associations
BMI – Basic Medical Insurance	JV – Joint Venture
CAGR – Compound Annual Growth Rate	M&A – Merger and Acquisition
CCCIEMHP – China Chamber of Commerce for Import & Export of Medicines and Health Products	MIIT – Ministry of Industry and Information Technology
CAPC – China Association of Pharmaceutical Commerce	MOFCOM or MOC – Ministry of Commerce
CFDA – China Food and Drug Administration (predecessor of NMPA)	MOF – Ministry of Finance
ChP – Chinese Pharmacopoeia	MOH – Ministry of Health
CMH – China Monitor Health	MoHRSS – Ministry of Human Resources and Social Security
CNCM – China National Corporation of Medicines	MNCs – Multinational pharmaceutical companies (<i>in the context of this guide</i>)
CNIPA – China National Intellectual Property Administration	MR – Medical Representative
CNY – Chinese Yuan	NBS – National Bureau of Statistics
CPA – Chinese Pharmaceutical Association	NCGHSR – National Coordination Group for Healthcare System Reform
CPIIC – China Pharmaceutical Industry Information Center	NDRC – National Development and Reform Commission
CRO – Contract Research Organization	NH – Nicholas Hall & Co.
DRG – Diagnosis Related Groups	NHC – National Health Commission, successor of NHFPC
ED – Erectile Dysfunction	NHFPC – National Health and Family Planning Commission, predecessor of NHC
FDA/USFDA – U.S. Food and Drug Administration	NRCMS – New Rural Cooperative Medical System
FDI – Foreign Direct Investment	NMPA – National Medical Products Administration (formerly CFDA)
FIEs – Foreign Invested Enterprises	NHSA – National Healthcare Security Administration
FTCMs – Formulated TCMs	OECD – Organization for Economic Co-operation and Development
GCP – Good Clinical Practices	

OTC – Over the Counter	Institute under the CFDA
PHIIC – China Pharmaceutical Industry Information Center	SOE – State Owned Enterprise
PRC – People’s Republic of China	SPAC – State Pharmaceutical Administration of China, predecessor of SDA
QA – Quality Assurance	STD – Sexually Transmitted Disease
QC – Quality Control	TC – Therapeutic Class
R&D – Research and Development	TCM – Traditional Chinese Medicine
RDPAC – R&D-based Pharmaceutical Association Committee in China	UEBMI – Urban Employee BMI
SATCM – State Administration of Traditional Chinese Medicine	URBMI – Urban Resident BMI
SDA – State Drug Administration, predecessor of SFDA	URRBMI – Urban and Rural Resident BMI (URBMI+NRCMS)
SFDA – State Food and Drug Administration of China (predecessor of CFDA)	USTR – US Trade Representative
SAMR – State Administration for Market Regulation, governing body of NMPA	VAT – Value Added Tax
SIPO – State Intellectual Property Office	VC – Venture Capital
SMEI – Southern Medicine Economic	WM – Western medicine
	WHO – World Health Organization
	WTO – World Trade Organization

EXECUTIVE SUMMARY

By James J. Shen, Publisher and Managing Editor, WiCON/Pharma China

China's economy appears to be reaching the bottom of a cyclical slowdown as 2019 draws to a close, aided by an agreement that will prevent further tariff increases on goods shipped to the U.S. and de-escalate a trade war that's battered the global economy. Domestic stimulus efforts, ranging from tariff cuts to support for infrastructure spending, are also buoying sentiment. But then, coronavirus hit Wuhan and infection exploded in the city and quickly spread nationwide and even internationally, clouding the country's economy once again.

Things were not so pretty with the pharma industry either at the beginning of 2020. The Round 2 Purchase Tender of the National Level Centralized Drug Purchase Program concluded on January 17. The average price reduction by prevailing suppliers in the Round 2 is reported to be 68% while the highest single price reduction was 97%. Leading domestic players including Kelun Pharma, Qilu Pharma, Hengrui Medicines, Fosun Pharma and Yangzijiang Pharma emerged as big winners, as only four out of 26 participating foreign companies won bids for five originator products after big price cuts. Bayer was also the boldest and it reduced price of its Acarbose by 91% to win.

In the supposedly lucky *Year of the Pig* (2019), MNCs continued to see robust China business growth in amid a market vacuum before flooding of local GQCE products. Such admirable performance was achieved following negotiated NRDL listing and successful 4+7 tender bids, though no information is available about their bottom-lines. Besides, MNCs actively recalibrated their China strategies, business model & objectives and investment plans adapting various structural issues of the Chinese pharmaceutical market. Reorganization of MNC businesses in China, which began a few years back, continued in 2019.

Despite their surprise short-term gains ahead of the storm, it is by no means a smooth-sailing voyage forward for MNC pharma companies in China last year. While they have been busy introducing newer, innovative drugs to China at unprecedented speed, foreign pharmas' older medicines have come under pressure in a bulk procurement scheme that's cutting some off-patent drugs' prices through a bidding process.

Even IQVIA has lowered its Chinese pharma market growth project to 3%-6% annually before 2023 in its latest report, *The Global Use of Medicine in 2019 and Outlook to 2023*.

Foreign companies are taking enormous risks to do business in China. They are navigating an unprecedented array of risks, from slowing growth to the trade war and civil protests in Hong Kong. The latest saga of NBA ban in China unveils the minefield even further. But that hasn't stopped many of them from pushing deeper into the vast Chinese market.

According to the Chinese calendar, 2020 will be the *Year of the Rat*, which *Fengshui* masters say will be another year of extensive change as the universe continues in its

accelerated transitional period but, given the rat's traits, the world will be equipped to cope.

The U.S.-China trade war, political instability and a weak global economy all conspired to produce a tough 2020 for the Asia-Pacific, according to an article from *The | Diplomat* by Anthony Fensom.

Chinese pharma growth slowed further in 2019 amid a gloomy outlook

The Chinese pharma growth continued to cool in 2019 as a result of healthcare cost containments, 4+7 trial and its expansion, and introduction of rationalization schemes such as DRG, among other factors.

The three major Chinese drug terminal markets rose 4.8% in 2019, reaching a total of CNY 1,795.5 billion at retail sales prices, recently released SMEI data shows. This figure does not include drug sales through private hospitals and clinics, as well as village clinics. When they are accounted, the over Chinese drug market size in 2019 is projected to exceed CNY 2 trillion.

Separately, the overall Chinese drug market is estimated by PHIIC to rise 4.2% to CNY 17,141 billion in 2019. The center projects sales of 25 drug products covered by the 4+7 trial to shrink 1.18% by value and rise 12.16% by volume in 2019 in representative hospitals covered by PHIIC. It also estimates the Chinese sales value of innovative drugs to be CNY 11.12 billion in 2018, a 40% jump from CNY 8.06 billion in 2017. Such sales were equally shared by novel chemical drugs and biologics in 2018.

The Chinese pharmaceutical market is expected to grow slower at 4% in 2019, according to Han Wu, President of Sinohealth. Nonetheless, he continued to maintain a positive outlook of the Chinese pharmaceutical market due to a mix of different drivers including the country's huge population base, aging Chinese population and rising prevalence of chronic diseases.

SMEI predicts the Chinese pharmaceutical manufacturing industry (eight medpharm sub-industries) to grow 10.1% in 2019 to reach CNY 267.2 billion. It further projects the Chinese drug market to grow 4.8% in 2019 (vs. 6.3% in 2018) to reach CNY 1,795.5 billion. The hospital, retail pharmacy and primary healthcare markets (terminal 1, 2 and 3 markets) are projected to grow 4.2%, 5.0% and 8.5% respectively in 2019, down from 5.4%, 7.5% and 10.2% in 2018.

NMPA continues drug regulatory system reform as it boosts support of drug innovation

The Chinese government made numerous major regulatory moves and introduced more regulations to advance reform in 2019.

China passed a number of key legislations relating to healthcare in 2019. The National People's Congress (NPC) passed the *Vaccine Administration Law of PRC*, which stipulates the "strictest" management by requiring a whole-process supervision system and toughening penalties on producing and selling fake or substandard vaccines. As the country's first legislation dedicated to vaccine management, the new law went into effect on Dec. 1, 2019.

The NPC also adopted in August 2019 the amendment to the *Drug Administration Law of PRC*, which will give greater leniency to people who import small amounts of medicines which are unapproved in China but sold legally overseas. Under the previous law, such drugs were classified as "fake drugs". The amended law has 155 articles in 12 chapters and it went into effect on December 1, 2019.

The NMPA later issued a document promoting implementation of the newly amended *Drug Administration Law of PRC* in September 2019. In the document, the agency confirmed withdrawal of GMP and GSP certifications, while strengthening random inspections of GMP and GSP compliance.

Before the end of 2019, the NPC adopted the *Law on Promoting Basic Medical and Health Care*. As the country's first fundamental and comprehensive law on basic medical and health care, the law will take effect from June 1, 2020.

On the front of drug registration, the CDE accepted a total of 8,056 drug registration applications (by application numbers and excluding 2nd review applications) in 2019, up from 7,428 applications in 2018, according to Yaozh.com recompiling NMPA data. Among the total, 6,459 applications are for chemical drugs, 416 for TCMs and 1,158 biologics.

To continue its overhaul of the drug evaluation and approval system and support innovative R&D, China also introduced many more new rules and regulations in the area of drug registration in 2019. Such includes the NMPA's *Announcement over Matters Related to Further Improving Linked Evaluation and Approval of APIs, Excipients and Packaging Materials Used in Drug Products* in July 2019 and the *Guidelines for Use of Real-World Data to Support Drug R&D and Evaluation (Interim, 2020#1)*, in January 2020.

Into the new year, the State Administration of Market Regulation, the governing agency of NMPA, announced its legislation plan in 2020 on March 27 this year. The agency plans to draft and submit seven laws and regulations for approvals, as well as 48 departmental rules and regulations including the *Provisions for Registration of Drug Products* and the *Provisions for Control of Drug Manufacture*, which were issued in March 2020 and went into effect on July 1, 2020.

Meanwhile, China moved to ensure full-process regulation of vaccines, from manufacturing to inoculation. But there were few developments for internet drug sales and the policy for online drug transactions is still under discussion via public comments,.

Over drug pricing, the NDRC (later SAMR after government reorganization) continued to flex its muscles under the flag of anti-monopoly and policing of shortage drug prices. On the other hand, the NHSA issued a new policy, *Opinions for Perfecting Contemporary Drug Price Regulation (Yi Bao Fa 2019#67)*, in December 2019 for immediate effect.

Most recently in June 2020, the NHSA released its second draft of the Guidance Opinions for Drug Price and Tender Procurement Credit Rating System. Major provisions of the document include: 1) setting up the drug price and tender procurement discredit list; 2) introducing credit rating of pharmaceutical enterprises; 3) tiered handling of discredit and

violation practices and 4) publication of discredit handling information.

Healthcare reform remains in deep water and preoccupied with cost containment growing shortages

To lighten the fiscal financial pressure, ten central government agencies led by the NHC issued a new document, *Notice on Promoting Streamlined Healthy Development of Social Capital in Medical Services*, at the beginning of 2019.

The NHC held a press conference in April 2019 during which a senior health official outlined the future direction of healthcare reform. As its next steps, China will deepen reform in the pharma sector through facilitating the country's essential drug system, improving the 4+7 trial, consolidating the GQCE evaluation and accelerating electronic drug tracing system building.

By the end of May 2019, the State Council has moved to incentivize the growth of private medical institutions with streamlined approvals and greater policy support as experts underscored the importance of enabling more talent flow to the private medical sector. The cabinet decided to expand the room of development for private medical institutions. Employees of public hospitals may now apply for the opening of private medical facilities while they are still in service or on suspension from duty without pay.

The State Council later issued a new document, *Notice on Major Tasks of Deepening Healthcare System Reform in 2019*, in June. The document laid out 15 new policy documents to be researched and formulated this year including the list of encouraged generic drugs, as well as other policies relating to streamlining use of medical consumables and centralized public hospital drug purchase tender.

Subsequently, XIONG Xianjun, Director General of the Pharmaceutical Service Administrative Department of NHSA, announced that the national level centralized drug tender purchase scheme shall be expanded further in 2019. Besides, China will set up new medical alliances in 100 cities and 500 counties across the country in 2019, according to Xinhua News quoting a NHC official at an earlier press conference in the same month.

The country also has big plans for primary healthcare. The nation's policymakers want one general practitioner for every 2000 residents by the year 2030 – which means training 500,000 GPs in 12 years to more than triple the current GP workforce. The NHC also issued a basic standard for community healthcare facilities, requiring at least 30 beds to be open for patients in each hospital, and the utilization rate for sickbeds should above 75%.

Four central government agencies led by the NDRC issued the *Work Plan for Building Regional Medical Centers* and a notice to establish national and regional mental medicine+CNS centers in November 2019 to facilitate supply side reform in the healthcare sector and implement Healthy China initiative.

Fast forward to the new year, the 2020 National Primary Healthcare Teleconference was held in January 2020 during which the Chinese government set the goals for a primary healthcare system of higher quality and efficiency with elevated capacity building in 2020.

On Centralized hospital drug purchase tenders, the State Council Issued a policy document, *Trial Plan for Nationally-Organized Centralized Drug Purchase and Application*, in January 2019 to lay out the roadmap of this important experiment (4+7 trial). Subsequently, The NHSA sought to advance the 4+7 trial expansion with a new document, *Notice on Relevant Arrangements for Expanding the National Centralized Purchase and Application Trial*, in August 2019. By November 2019, the Healthcare Reform Leaders Group of State Council released the *Certain Policy Measures for Further Deepening Pharmaceutical and Healthcare System Reform through Centralized Drug Purchase and Use* to deepen and expand the experiment of national level centralized drug purchase and use trial nationwide.

There were none but one development in the area of essential drugs last year. In January 2019, the NHC and SATCM issued a joint document, *Notice on Further Strengthening the Management of Essential Drug Inventory and Application by Medical Institutions*, which provides a detailed roadmap and reinforces requirements for prioritized inventory and consumption of essential drugs in all public medical institutions.

As for major moves of cost containment by China last year, the NHSA initiated the National DRG Trial in a May 2019 teleconference. Later in October 2019, the NHSA issued two documents on diagnosis-related groups, the *Technical Guidelines for China Healthcare Security-Diagnosis Related Group (CHS-DRG) Grouping and the Payment & CHS-DRG Grouping Plan*, in a move to implement the DRG payment system reform trial.

The NHC introduced the first batch of the *List of Drugs Subject to State Rationalization Surveillance and Control (Chemical Drugs and Biologics)*, or the so-called the national adjuvant drug list, in July 2019.

The NHSA and MOHRSS released the *2019 National Reimbursement Drug List (NRDL)* under the BMI, WRI and Maternity Insurance in August 2019. The latest 2019 NRDL contains 1,322 Western medicines, 1,321 formulated TCMs (including 93 ethnic medicines), and 892 TCM crude drugs. There are an additional 128 drugs (including 109 WMs and 19 formulated TCMs) proposed for negotiation, all of which have high clinical value and more expensive.

In the meantime, the NHSA initiated and concluded a new round of access negotiation for the 2019 NRDL in November. Out of the 150 premium drug products from over 70 manufacturers which were selected for 2019 NRDL listing through negotiation, experts chosen by the NHSA and MOHRSS succeeded in reaching agreements for 97 such drug products.

By the end of 2019, the National Drug Usage Monitoring Platform was launched, according to the NHC Information Center. It is reported that 8,840 medical institutions have registered on the platform, which already has 600,000 average daily visits.

Fast forward to the new year, the General Office of the National Health Commission (NHC) issued in January 2020 the *Clinical Pathways for Relevant Disease Groups (2019)* for reference by all levels of healthcare agencies and all levels/categories of medical institutions.

In the same month, the 2020 National Primary Healthcare Teleconference was held in

during which the Chinese government set the goals for a primary healthcare system of higher quality and efficiency with elevated capacity building in 2020.

The Central Committee of the Chinese Communist Party and the State Council issued a major policy, *Opinions on Deepening Medical Insurance System Reform*, in March 2020. Guiding principles of the document is to build a uniform and multi-tiered medical insurance system with universal population enrollment, balanced fund raising from urban and rural areas, clear obligations and responsibilities, and appropriate coverage. The role of the BMI fund in strategic buying is upheld to promote coordinated development of medical insurance and high-quality healthcare services, and to support implementation of the Healthy China initiative.

Similarly, three central government agencies, the NHSA, the MOF and the STA issued the *Notice on Urban and Rural Resident BMI Tasks in 2020* in June 2020. The goal is to facilitate the central government decision to establish a uniform urban and rural resident BMI as well as critical illness systems.

The State Council issued a new document, *Opinions on Major Departmental Task Assignments to Facilitate the Government Work Report of the State Council*, in June 2020. It is provided that China will reform its disease prevention and control system, beefing up capacity building for infectious disease prevention and treatment, refine infectious direct reporting and early alert system, and persist on epidemic information transparency. Relevant policies shall be introduced before the end of 2020.

Paradigm begins to shift for Chinese pharma as MNCs struggle to fit in with the new normal

Structural issues with the Chinese healthcare system continued to haunt the pharmaceutical industry in 2019. Notwithstanding the touted pharma industry ambitions of the Chinese government, slogans are nothing but pies in the sky when it comes to paying for better medicines. The healthcare reform has long been hijacked by cost containment and gone astray from the pledged path of improving efficiency and fixing structural flaws. The crashing course of reform is deeply rooted in the growing contradictions between wishful goals and healthcare financial reality, as well as among different government policies and their pursuits.

China is doubling down on its efforts to radically overhaul its healthcare system by driving down prices of off-patent drugs to free up state funds for novel, cutting-edge therapies. The campaign is putting pressure on profit margins for both foreign and domestic drug makers. The 4+7 trial that started in late 2018 had seen prices plunge by more than half, while cheaper generic drugmakers undercut their global peers. Its “success” emboldened Beijing to expand the program nationwide in 2019 and then initiate a second round of supply contracts for its public hospitals.

With tax and other revenues drying up and under increasing threat of BMI system deficit amid a looming Chinese economic downturn, local governments are pressured by both the central government and the public to do more for healthcare with less financial resources. As local governments assaulted the pharma industry above the table with wave after wave

of cost containment measures, public hospitals also squeezed drug companies under the table for funds through a variety of schemes. Shortage of low cost but clinically essential medicines has become widespread, forcing the central government to step in and often intervene administratively.

Pushed to the corner, the Chinese pharmaceutical industry is now at the brink of business bottom-lines. Under pressures of escalating anti-corruption campaigns, increasingly sophisticated cost containment measures as well as policy shifts in drug pricing and reimbursements, both domestic and multinational drug companies had no choice but to make dynamic changes so as to meet the contemporary challenges of the Chinese healthcare business today.

The pharmaceutical industry is reeling: Chinese drugmakers issued a flood of profit warnings last year, while their global counterparts such as AstraZeneca Plc and Sanofi cited the procurement plan as a damper for earnings. Foreign pharmaceutical giants are pivoting toward innovative treatments to make up for the tumbling sales of their off-patent drugs after local rivals undercut them on pricing.

The most noteworthy development in China healthcare throughout last year was implementation of the National Level Centralized Drug Purchase and Use Program in four central municipalities and seven provincial level major cities (4+7 trial), which was first trialed in late 2018. The trial began with centralized purchase of 31 drug products passing generic quality and clinical equivalence (GQCE) evaluation in 11 trial site cities and expanded in 2019 to 25 provinces and regions and 35 drug products in September 2019.

By early 2020, five central government agencies led by the NHTA initiated the Round 2 of the National Level Centralized Drug Purchase and Use Program, which is set up to purchase 33 drug products from therapeutic categories of diabetes, hypertension, oncology and rare diseases. The average price reduction by prevailing suppliers in the Round 2 to be between 60% and 80% with the highest single price reduction at 93%. Bayer AG's diabetes drug acarbose had its price slashed by 80%.

In the aftermath of the coronavirus outbreak, industry watchers said in March 2020 that many ongoing drug trials are facing disruptions with people in clinical drug testing, unable or unwilling to report to hospitals for fears of catching the virus. Along with clinical trials, the Pharma industry may even face some shortages of APIs supplied by the Chinese pharma companies.

It all comes down to mounting challenges and roadblocks ahead for pharma MNCs in China, thus hampering near term and future prospects though opportunities continue to remain in select areas.

As the 4+7 trial and its expansion program advanced, the market for MNC off-patent originator drugs at tier 1 and 2 Chinese cities shrank quickly. Many MNCs responded by pushing further into lower tier urban and even rural areas. Both Sanofi and Pfizer are believed to be raising their bets on the county level hospitals and community healthcare facilities. At the same time, an array of MNCs including Pfizer, Lilly, GSK, Merck and Allergan hurried to jump on the China's speeding e-commerce train for untapped

opportunities.

In addition, big pharma companies are testing different approaches. On the one hand, they are speeding up the disposal of manufacturing and drug development facilities, as well as licensing of even core off-patent originator product assets to Chinese companies in order to reduce exposure to systemic China risks. Recent examples include spinoffs of Suzhou Novartis and GSK (Suzhou) facilities to Jiuzhou Pharma and Shanghai Fosun respectively, as well as a deal between Eli Lilly and Eddingpharm for promotion and distribution of Ceclor and Vancocin, two well-established Lilly antibiotics, in China

MNCs will be pressured to offload more of their off-patent originator products to domestic players in future, as prices are to be pushed so low in future that foreign companies simply cannot afford to promote these products in China at their global standards.

On the other hand, MNCs are also changing their R&D strategy in China, shifting from owning and operating their own research centers in the country to focusing more on building partnerships with Chinese research companies. Numerous foreign companies closed or downsized their Chinese R&D operations with slashed investments. At the same time, some companies continued to invest in drug development and translational research along with more local partnerships.

Indeed, MNCs must test the Chinese market with their different strategic options and find their own successful and sustainable path forward. Whatever the right formula, however, the bottom line, which I would caution all MNCs equally, is to stay away from integrating with Chinese characteristics along the way. Always remember, being different from your local competitors is probably the most important reason why reputable MNC pharma companies are still enjoying certain prestige among the Chinese people and therefore deserve certain climate-proof market share in the country.

In the meantime, 312 A Share-listed Chinese medpharm companies reported their 2019 performance by April 30, 2020. 40 of the 312 such companies had revenues exceeding CNY 10 billion (up from 34 in 2018) and 26 of them had net profits above CNY 1 billion in 2019. On the other hand, nine of them had losses above CNY 1 billion, including Hengkang, Yatai Pharma and Jilin Pharma, in the same year.

According to a separate report, 80% of listed Chinese pharmaceutical companies increased their R&D spending and seven such companies saw over 50% R&D spending growth in the first three quarters of 2019. Besides, 14 such companies invested more than 10% of their revenues in R&D.

There was a total of 63 fund-raising deals for startup companies in the Chinese biotech and medpharm sectors in the first half of 2019, totaling US\$1,645 million, according to vcbeat.top. But trade tensions are undermining the flow of Chinese venture capital to US Biotechs, which have seen a drastic drop in Chinese funding for the industry.

Investment return of Chinese biotech startups is becoming an increasing concern. By late 2019, a total of 12 pre-profit Chinese biotech startup companies have won listing at the Hong Kong Stock Exchange (HKSE) from April 2018, when HKSE altered its rules to allow listing of startup companies which have yet to turn profitable. Seven of them saw

their share prices falling below their IPO level with Ascleitis dropping as much as 75%.

The number of recorded mergers and acquisition deals in China's pharmaceutical sector remained high in 2019, with 437 cases and total deal value climbing 12 percent to US\$22.1 billion, a 4-year high thanks to overseas investors' upbeat sentiment and mega deals in the private equity sector, according to a recent PwC report. These results also reflect favorable policies such as nationwide volume-based procurement, dynamic adjustment to the National Drug Reimbursement List, and encouragement of innovation, as well as the promotion of new capital market listing regulations.

China sends conflicting signals in the field of pharma IP but the U.S.-China Phase 1 Trade Deal May Be A Game Changer

Conflicting signals continues to be seen in the Chinese pharma IP space in 2019. More innovative drugs from research-based MNCs were approved through accelerated paths, as the NMPA begins to take concrete steps to accept foreign clinical data so as to expedite review. On the other hand, central and local governments continued to push substitution of off-patent originator drugs with bioequivalent generics, promoting indigenously-developed local new drugs, introducing more negotiation and tender measures to sharply lower prices of both generics and patent medicines.

Fast forward to January 2020, despite various skepticisms on the concluded “phase 1” US-China trade deal, multinational drugmakers found much to be cheerful about.

Specifically, the document includes three provisions related to pharmaceutical patent dispute resolution, patent term extension and counterfeit medicines, promising to strengthen protection for drugs at a time China’s regulatory agency has sped up reviews and shortened the time gap between overseas and Chinese OKs.

The first provision, Article 1.11, stipulates that China would set up a mechanism commonly known as patent linkage in the US, as established in the Hatch-Waxman Act of 1984. It functions “much like a traffic control system” involving the FDA, the USPTO and the court.

Furthermore, according to Article 1.12 of the trade deal, China has committed to extending patent terms for unreasonable, lengthy delays that aren’t the applicant’s fault. The compensation will not exceed 5 years and the resulting effective patent term – counting from the date of marketing approval in China – will be no more than 14 years.

Lastly, Article 1.18 prods China to take quick action against counterfeit pharmaceutical products including API, bulk chemicals or biological substances. Among them is a requirement to share inspection information with the US and publish data on enforcement measures online every year, “including seizures, revocations of business licenses, fines, and other actions.”

Furthermore, the deal allows supplemental experimental data, which was forbidden in the past – meaning drugmakers can now add new evidence to support consideration of their patents after they first filed for it.

On March 6, 2020, the U.S. Trade Representative’s Office (USTR) released its *2019 Report to Congress on China’s WTO Compliance*, the 18th such report but perhaps the most insightful. Since 2018’s report, USTR’s assessment of China’s record in terms of complying with WTO rules and observing the fundamental principles on which the WTO agreements are based has not changed. China’s record remains poor. As detailed in 2019’s report, China’s trade regime has generated many WTO compliance concerns.

Despite Challenges, Long-Term Prospects and Opportunities Remain

The rapid transformation in China’s pharma industry, especially in innovative drugs, will benefit the leading MNCs and domestic companies, according to a 2019 CitiResearch report. The market share of the top 10 multi-national companies (MNCs) will rise to 25% in 2025 (from 16% in 2018), on Citi estimates, and of the top 10 Chinese companies to 28% (from 15%). MNCs will largely grow through innovative drugs, the biggest growth driver of the sector, and the domestic companies largely through generics and biosimilars. CitiResearch estimates MNCs’ patented drugs and China’s domestic innovation sales to grow at CAGRs of +60%/+50% in 2018-25E. Potential winners would be AZ and Merck among MNCs, and SBP, Hengrui and Hansoh among the Chinese companies.

China to open sector even further – After joining the ICH (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use) in 2017, the Chinese government has initiated major reforms to facilitate commercialization of innovative drugs. Clinical trial requirements and quality are moving towards global standards. All this could mean much faster growth for MNCs with innovative therapeutics, as well as for Chinese R&D leaders.

A series of legislative and regulatory reforms have prompted global players to reappraise their China strategies. Key drivers include (i) accelerated development and NMPA review processes, (ii) accelerated timeline for inclusion into the NDRL, albeit with price concessions, (iii) strong enforcement of intellectual property as Beijing seeks to broaden healthcare access to an increasingly larger urban middleclass population, with similar living standards to western markets. At the same time, it is clear to global players that returns for post LOE drugs will continue to decline given reimbursement reforms (hospital mark-ups, centralized procurement etc).

China’s entry into international organizations for drugs registration and development is catalyzing major reforms in the country’s pharma sector, the second largest in the world, and offers big opportunities to both global players and Chinese firms. CitiResearch expects the country’s pharma sector to grow at an 8% CAGR in 2018-25E, to CNY 2,708 bln (US\$393bn), led by 1) innovative drugs (15% from Chinese companies; 19% from foreign players – by value), 2) generics and 3) biosimilars. With the biggest growth driver being innovative drugs, the leading global players cannot afford to ignore China. In this Must C, we analyze each of these growth drivers and identify the biggest potential beneficiaries.

Innovation to drive top global players’ market share – The underdeveloped innovative drugs market in China is rapidly changing due to faster govt reimbursement and higher commercial insurance for imported innovative drugs. China is adopting global standards

in clinical trials, and policy reform is shortening waiting time for drug development & commercialization. Winners would be foreign players with innovative therapeutics and an established presence in China – AZ (18% pharma sales from China) and Merck (6%). R&D leaders in China should also benefit – SBP, Hengrui and Hansoh.

Consolidation to strengthen generics leaders – China, as a developing country, will rely mostly on generics for its universal healthcare. Mandatory biological equivalency tests will eliminate inferior generics and bring about consolidation in the sector through potential beneficiaries SBP, Hengrui and Hansoh.

Biosimilars market is in its infancy – Biosimilars are new to China, and hence Citi sees big potential in the segment before eventual crowding increases pricing competition. More reimbursements would make biologic therapeutics affordable. Early movers would benefit. In the long term, winners would need sustainable manufacturing and sales.

The Godsend window of opportunity for MNCs to recalibrate China strategy and reallocate resources

First and foremost, I think the current trade deal is more of a temporary truce than a reliable sustainable agreement. For the time being, China will need to deliver some of its promises right away to keep the U.S. happy and at bay, but the first potential flop point down the road may come around the third quarter of next year, when the U.S. presidential race reaches its critical phase. If China concludes then that its best interest is with Trump, we may see a prolonged opportunity window, which may even lead to some painstaking but meaningful reform eventually. Otherwise, expect turbulences.

Some experts argue that the Phase 1 Deal has set the Chinese purchase goal too high at US\$200 billion for the next two years and there is no way China can achieve this. To this, I would say opportunity knocks for the MNC pharma companies, although such luck may not be sustainable. But who knows, it's China.

Additionally, the pharmaceutical market is one area China can demonstrate some concrete changes to appease the U.S. for now. In fact, many reforms, both regulatory and IP, are to the country's own benefit, which include enhanced access to better medicines by at least some of its population and more incentives for domestic drug innovation.

While such are positive developments for MNC pharma companies, it is important not to fall for the trap one more time. As I said, the Chinese market opportunities due to the MNCs are driven more by their product portfolios than the size of their presence or investment in China. Yes, MNCs may need to have at least some manufacturing and product development capacity in China, given it is a larger market even at the barebone, but such should be business decisions made on top of long-range strategic vision, rather than market access quid pro quos.

The biggest catch for long term success of MNCs in China is whether their core products are innovative, competitive and differentiated enough against their peers and domestic rivals? I guess what's tied with this is whether these companies are prepared to make the absolutely best effort protecting/policing their own IPs and are vigilant/smart enough not to create and foster their own competitors. I would strongly urge companies to start by

reviewing and recognizing their past mistakes with China business.

The historical window of opportunity is now at the door for MNCs that are ready to recalibrate their China strategies and reallocate resources. The window could be just a few months or a bit longer, during the timeframe forex control may become more relaxed and reactions to major business decisions are expected to be more benign. In any event, I would advise companies to plan and act sooner than later.

Be Ready for the Dire Aftermath of the Post-Pandemic China Market

Although the coronavirus outbreak appeared to have eased in China by April 2020, many experts continued to be alarmed by the possibility of renewed outbreaks in the country.

Even assuming the best scenario and China is back in normal business soon, the aftermath of this outbreak is still nothing short of daunting. The coronavirus outbreak overseas is still peaking overseas and global economy / demand tanked, which means the export-dependent China cannot recover on its own.

The standstill caused by the outbreak has triggered eruption of many Chinese economic and financial structural issues which are long overdue for correction. The danger of Chinese economic hard-landing or even total collapse seems inevitable.

Central and local governments will be strapped financially and they are set to bring healthcare cost containment to an unprecedented level. Long delays in payment and bad debts are likely to come back haunting businesses for a very long time. Six central government agencies, including the NHC, Ministry of Education, MOF, MOHRSS, NHSA and NMPA, already issued a new policy, Opinions for Strengthening Pharmacy Affairs Management of Medical Institutions to Promote Drug Rationalization, in late February for immediate implementation.

The ongoing coronavirus outbreak seems to be the final nail in the coffin of globalization. We are going to live in a very different world after the outbreak with restructured supply chain emphasizing domestic production of strategic products from masks, toilet paper to medicines. Already, U.S. politicians are talking about reactivating Puerto Rico as the country's future API production center, while Sanofi announced plans to build substantial API manufacturing capacity for EU.

Geopolitical conflicts among countries, especially between China and the U.S., are rising with growing ideological clashes. Quarrels over the origin of coronavirus outbreak has added heat to the fire. Cold war is almost inevitable, if it is not ongoing already. Sooner or later, nations and large businesses, including MNC pharma companies, may have to choose their camps.

It remains to be seen how things will evolve during and after the outbreak. Hopefully things will be calmer but we will see. For now, it is advisable to hold off on any investment plans or business ambitions in China.